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Adding LARC Services into Student Health

Introduction
Unintended pregnancy among young women continues to be an issue in the United States
(Finer & Zolna, 2011). Although several safe and highly effective contraceptives are available,
nearly half of all pregnancies in the United States are unintended, with the majority occurring
among women between the ages of 18-24, who are frequently college students, unmarried, low
income, or not planning to conceive (Finer & Henshaw, 2006; CDC, 2013). Unintended
pregnancies often result from inappropriate or inconsistent contraceptive use (Secura, Allsworth,
Madden, Mullersman, & Peiper, 2010), and one in five unintended pregnancies ends in abortion
(Pazol, Creanga, Burley, Hayes, & Jamieson, 2013). Long-acting reversible contraceptive
methods (LARCs) are safe and highly effective contraceptive methods that can be used to
prevent unintended pregnancy, but are currently only being utilized by a small portion of women
- 5% of contraceptive users - in the United States (Secura et al.; Mosher & Jones, 2010).
Based on the 2011 enrollment report, the patient population of Student Health and
Counseling Services (SHCS) of California State University, East Bay (CSUEB) consists of
approximately 13,160 enrolled students, of which 60% (7,959) are female and 40% (5,201) are
male, with an average age of 26 (Baker, Malhotra, & Weitzman, 2013; Office of Planning &
Institutional Research, CSUEB, 2012). An American College Health Association (ACHA)
survey conducted in spring 2010 found that the unintended pregnancy rate was reported as 4.9%
among CSUEB respondents compared to national rates of 5%. Among all 23 CSU campuses,
currently enrolled students are able to go to any nearby CSU, Student Health Services (SHS) for
care if needed, but none of the CSU SHS listed the provision of LARCs service on the SHS
home page by online search.
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Assisting students in maintaining their optimal health to allow them to pursue academic
and career goals is the main mission of Student Health and Counseling Services (SHCS, 2014).
According to the 2012 ACHA, approximately 65% of college students reported having sexual
partners within the last 12 months, and 49% of them reported not using any contraceptive
method (ACHA-NHCA II, 2012). Furthermore, in 2013, the American College Health
Association surveyed college students nationwide about contraceptive use, with a 34% response
rate that consisted of 96,611 respondents (ACHA-NCHA II, 2013). Of the respondents, 46.5%
reported not using any contraceptive methods during their last sexual intercourse within the past
30 days. The usage rate for intrauterine contraception (IUC) was reported at 5.5%, implant
contraception was reported at 2.4%, and birth control shot was reported at 4.3%. Therefore,
helping students prevent unintended pregnancy, especially freshmen and newly transferred
students, is one of the measures to help maintain their optimum health.
Previous studies have shown that misperceptions about LARCs, lack of access, lack of
education, and lack of training on IUC use among health professionals are common issues, and
may be the major reason for their underuse (Secura et al., 2010; Khan & Shaikh, 2013;
Kavanaugh, Jerman, Ether, & Moskosy, 2012). Family nurse practitioners can help these young
women make an informed choice about contraception by providing evidence-based information
and dispelling the misconceptions regarding LARCs. The purpose of this project is to provide
evidence-based information regarding LARCs use and discuss the integration of LARCs services
into a primary care-focused student health clinic.
Long-Acting Reversible Contraceptives (LARC)
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Long-acting reversible contraceptives (LARCs) include three types of intrauterine
devices and one type of implant that provide highly effective contraception, rapid fertility
reversal after removal, and are non-user dependent after placement.
Intrauterine contraceptives
The World Health Organization (WHO) supports intrauterine contraceptive (IUC) use in
adolescents starting from menarche with a level 2 recommendation, “benefits outweigh the risks”
(WHO, 2004). Additionally, IUC is considered to be a first-line choice contraceptive method for
both nulliparous and parous adolescents as recommended by the American College of
Obstetricians and Gynecologists (ACOG) Committee Opinion in 2007 (Deans & Grimes, 2009;
ACOG, 2007). IUC is one of the most effective contraceptive methods for unintended
pregnancies because it is long-acting, reversible, safe, and requires low user maintenance. After
adequate counseling, an IUC may be placed by a trained health care provider in an outpatient
clinic. Currently, the three IUC devices available in U.S. include the Copper T 380A (ParaGard)
and two levonorgestrel intrauterine systems (LNG-IUS), Mirena and Skyla (Deans & Grimes,
2009; Hatcher et al., 2011).
The Copper T 380A IUD was introduced in the United States in 1988. It is a nonhormonal, polyethylene T-shaped copper containing device with barium sulfate for x-ray
visibility, placed inside the uterus for contraceptive use for up to 10 years. The device is 36 mm
tall and 32 mm wide, and the total copper surface area is 380 ± 23 mm². The copper ions in the
device prevent fertilization and implantation (Hatcher et al., 2011). The Copper T can be used as
emergency contraception within five days of unprotected sexual intercourse (Hatcher et al., 2011)
and has greater than 99% efficacy at pregnancy prevention. High efficacy and long duration of
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use have made copper IUDs the most common contraceptive method in developing countries,
especially in China (Arrowsmith, Aicken, Saxena, & Majeed, 2012).
There are currently two levonorgestrel intrauterine system (LNG-IUS) options available
in the United States: Mirena and Skyla (Hatcher et al., 2011; Phelps, Murphy, & Godfrey, 2011;
Medscape Reference, 2014). The first LNG-IUS, Mirena, was approved for use in the United
States in 2000 and is a small T-shaped IUC device that contains 52 mg levonorgestrel, and
initially releases about 20 mcg daily into the uterine cavity, with the amount gradually
decreasing to 10 mcg daily by the fifth year (Hatcher et al., 2011; Phelps et al., 2011; Medscape
Reference, 2014). The device is made of a Nova-T polyethylene frame with barium sulfate for
x-ray visibility and a cylinder of a polydimethylsiloxane-levonorgestrel mixture molded around
the vertical arm. The device is 32 mm tall & 32 mm wide (Hatcher et al., 2011; Medscape
Reference, 2014). It is one of the most effective contraceptive methods and also has a number of
non-contraceptive health benefits which include: decreasing menstrual blood loss, alleviating
painful menstrual cycles, and protecting the endometrial layer during estrogen replacement
therapy (Medscape Reference, 2014; Mansour, 2012). The efficacy of the LNG-IUS in
preventing pregnancy is greater than 99%, and it is approved for contraceptive use for up to 5
years.
The second LNG-IUS, Skyla, contains 13.5 mg levonorgestrel and is the newest IUC,
added to the US market in 2013. The device is 30 mm tall and 28 mm wide and releases about
14 mcg per day of levonorgestrel into the uterine cavity initially (Medscape reference, 2014).
The amount of levonorgestrel gradually decreases to 5 mcg daily after three years of use
(Medscape Reference, 2014). Levonorgestrel acts by thickening the cervical mucus to prevent
sperm from entering into the uterus and changing the endometrium structure to prevent
4
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implantation. This IUS prevents pregnancy for up to 3 years at greater than 99% efficacy. It
also can provide non-contraceptive benefits to some female users with a history of painful or
heavy menstrual cycles by decreasing the lining of the endometrial layer, decreasing menstrual
blood loss, and preventing painful menstrual cycles (Hatcher et al., 2011; Medscape Reference,
2014; Mansour, 2012).
Etonogestrel contraceptive implant
The ENG-Implant is a single thin implant rod 4 cm long and 2 mm in diameter that is
made of ethylene vinyl acetate and contains 68 mg of etonogestrel (3-keto-desogestrel), which is
placed under the skin in the medial upper arm. The ENG-Implant provides unsurpassed
contraceptive efficacy by inhibiting ovulation and thickening cervical mucus. It also provides
effective contraception with a very low level of progestin and follicular phase estrogen that has
been well tolerated, reportedly has decreased weight changes among users, and rare medical
contraindications. It also decreases menstrual blood loss and painful menstrual cycles for at least
3 years. The effectiveness of the ENG implant to prevent pregnancy is greater than 99% (6
pregnancies in 20,648 cycles). Return of fertility is rapid among users with etonogestrel levels
undetectable within 1 week (Davies, Feng, Newton, Van Beek, & Coelingh-Bennink, 1993); 44
of 47 women who were studied with ultrasound and serum progesterone levels ovulated within 1
month post removal (Croxatto & Makarainen, 1998).
Besides preventing unintended pregnancies, non-contraceptive benefits of LARCs can be
used to help individuals with chronic medical conditions, such as anemia, heavy menstrual
bleeding, and painful menstrual periods (Hatcher et al., 2011). LARCs will be suitable for
patients with chronic conditions who take medications which can cause adverse effects. LARCs
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are especially appropriate for patients who are treating their medical conditions with teratogenic
medications (US MEC, 2012).
Local problem
The Need for LARC services
There are a few triggers leading this project’s initiation. First, highly effective longacting reversible contraceptive methods are not available at SHCS, even though most other
contraceptive methods are provided. Second, students who are interested in LARC methods are
referred to off-campus Planned Parenthood (PP) clinics or nearby community health centers for
LARC placement services, but the nearby PP clinics have been closed due to financial
difficulties (Mieszkowski, 2010). Also, according to an on-line search, none of the 23 California
State Universities (CSU), student health clinics currently lists the service of LARCs on their
student health clinic’s home pages.
Unintended pregnancy is a substantial social and economic problem in the United States.
Even though there are many contraceptive choices available, 49% of the 6.4 million pregnancies
every year in the United States are unintended (Trussell, 2007). Among women 15-44, the rate
of unintended pregnancies was 51 per 1,000 women, with the majority occurring among women
aged 18-24, who are often unmarried, low-income, low-education level, and minority ethnicity
(Finer, 2006). In the U.S., unintended teenage pregnancy has a significant fiscal impact, costing
taxpayers at least $10,900,000,000 annually (H.R.2678, 2011). In 2009, there were nearly
750,000 teenage pregnancies, and a total of 409,840 infants were born to 15-19 year-olds with a
live birth rate of 39.1 per 1,000 women (CDC, 2011). Women with an unintended pregnancy
will usually delay prenatal care, which can affect the health of both the fetus and the woman.
6
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Pregnant teenagers also face more medical and socioeconomic concerns such as increased risk of
pre-term delivery, low birth weight, neonatal mortality, delays to antenatal care, lower
educational levels, higher rates of poverty, and other poorer “life outcomes” compared with
women in their twenties and thirties (CDC, 2011; Chen et al., 2007).
According to the 2013 American College Health Association survey of contraception use
among U.S. college students (ACHA-NCHA II with n=96,611), the IUC usage rate was 5.5%.
Of the respondents, 46.5% reported not using any contraceptive methods during sexual
intercourse within the past 30 days. About 18.8% of the female respondents reported using
emergency contraceptive pills (“the morning after pill”) in the last 12 months and 1.9% of the
respondents reported experiencing an unintended pregnancy in the past 12 months.
Inappropriate or inconsistent contraceptive use is the most common cause of unintended
pregnancy, (Secura et al., 2010) and approximately one in five unintended pregnancies ends in
abortion (Pazol et al., 2013). Due to the misuse or infrequent use of contraceptives, unintended
teen pregnancy in the Unites States continues to be a persistent problem (Martinez, Copen, &
Abma, 2011). Prevention of unintended teen pregnancy is of particular importance to the health
and quality of life for young people throughout the United States. Additionally, improving
maternal health is one of the United Nations Millennium Development Goals for 2015 (UNDP,
2012). Recommended strategies will effectively improve maternal health, such as increased
contraceptive use and improved health care access.
Student Health Services are outpatient clinics on college campuses that offer primary
medical care and women’s health care to students. Generally, they are staffed by physicians,
nurse practitioners, registered nurses, medical assistants, and counselors. The mission of the
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Student Health Services is to assist students in achieving their academic and career goals by
providing resources to help them maintain optimal health and to provide high quality, low cost
health care to all enrolled students. Highly effective long-acting reversible contraceptive
methods, such as the implant contraceptive and IUC, are not listed as available services at the
majority of on-campus Student Health Services (SHS) in California.
Healthy Campus 2020, initiated by American College Health Association’s (ACHA)
Healthy Campus Coalition and derived from Healthy People 2020, targets reducing unintended
pregnancy, increasing contraception use, and facilitating emergency contraception access at SHS
to meet the student family planning objectives by 2020. Long-acting reversible contraception
(LARC) methods are very safe and effective contraceptive methods that can be used to prevent
unintended pregnancy, but are currently only being utilized by a small portion of women in the
United States (Secura et al., 2010; Mosher & Jones, 2010). Increased highly effective
contraceptive method use and increased access to such health care options are recommended as
strategies to improve family planning and maternal health by United Nations (UNDP, 2012).
Integrating LARC services into College Student Health Services is needed to help the healthcare
system effectively meet these goals.
Intended Improvement
The goal to add the highly effective, non-user dependent LARC methods to the services
of SHCS for students will enhance SHCS’s mission to provide the best quality, low-cost health
care to help students maintain their optimal health in order to pursue their academic and career
goals.
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The first objective of this project is to study the clinical contraceptives services currently
provided and continuing usage by individual students. The second objective is to promote
contraceptive use and add the service of highly effective LARC methods for sexually active
students to lower students’ stress by reducing the number of off-campus referrals, to prevent
unintended pregnancy, and to help students maintain optimal health conditions to pursue their
university degrees and careers. The third objective is to collaborate with the health promotion
department to educate students and to promote the use of highly effective contraceptives.
The purpose of this proposal is to add highly effective long-acting reversible
contraceptives (LARCs) service at SHCS for university students to help maintain their optimal
health, to treat medical conditions, and to prevent unintended pregnancies.
Review of the Evidence
Also, many misperceptions regarding the use of IUC among patients and health providers
need to be addressed (Khan & Shaikh, 2013; Mansour, 2012) prior to integration of IUC services
into a primary care focused student health clinic. Providing the most up-to-date and accurate
information about LARC methods will assist in dispelling rumors and myths. Myths can be
defined as a belief, often false or unproven, that have accrued around a person, phenomenon, or
institution. Rumors can be defined as unverified information of uncertain origin received from
another (American Heritage Dictionary, 2000). Misconceptions and rumors have negatively
impacted the uptake of LARC methods. The facts presented below will help address common
misconceptions about the LARC methods.
IUC & the Facts
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Although IUCs are safe, highly effective, and economical contraceptive methods, they
are currently underutilized, especially among adolescents. Clinical providers are still reluctant to
provide the service due to misperceptions stemming from the 1970s. Memories remain of the
Dalkon Shield product, an IUC released in 1971 and withdrawn from the market in 1974, whose
unique shape and its multifilament string tail caused removal difficulties, pelvic infections, septic
abortions, and other infections (Cheng, 2000). Approximately 200,000 claimants worldwide
filed lawsuits against the manufacturer even after the product was withdrawn from the market in
1974.
Myths about IUC use and function abound, nevertheless the U.S. Medical Eligibility
Criteria for Contraceptive Use, 2010 (U.S. MEC), and the U.S. Selected Practice
Recommendations for Contraceptive Use, 2013 (U.S. SPR) for health care providers are
excellent resources for education, implementation, continuing care, and management of IUC.
A common misperception is the mechanism of action of an IUC. An IUC is not an
abortifacient (Phelps et al., 2011). IUC alters the uterine environment by promoting a foreignbody reaction inside the uterine cavity that prevents fertilization and/or implantation (Hatcher et
al., 2011; Mansour, 2012). With the copper IUD, copper repels sperm and generates an
inflammatory foreign body reaction to prevent fertilization (Hatcher et al., 2011; Phelps et al.,
2011). The LNG-IUS works by releasing high concentrations of LNG within the uterine cavity,
which results in endometrial atrophy and thickens the cervical mucus to create a barrier to sperm
penetration, thereby preventing sperm-egg binding (Hatcher et al., 2011; Phelps et al., 2011).
Historical problems with the Dalkon Shield have falsely created the belief that the IUC is
not appropriate for nulliparous women. The WHO and the ACOG, support the use of IUC in
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both nulliparous and parous adolescents (WHO SPR, 2004; ACOG, 2007; Mestad et al., 2011;
Godfrey et al., 2010). IUC for nulliparous use is a level 2 recommendation from the U.S.
Medical Eligibility Criteria; the benefits of IUC generally outweigh the risks for women who
have not had children (US MEC, 2010) (see appendix L).
Similarly, misperceptions about infertility persist. An IUD does not cause infertility and
does not limit one’s chances of getting pregnant in the future. Most cycles in women using
LNG-IUS are ovulatory because there is no reduction in estradiol levels (Mansour, 2012). For
women wanting to conceive, the 12-month pregnancy rate (92%) following removal of LNGIUS is similar to women using natural family planning (Mansour, 2012). Historically, there was
concern that IUC increased the spread of sexually transmitted infections (STIs). If STIs are not
treated, they can scar the fallopian tubes and prevent women from getting pregnant. Research
shows that today’s IUC does not increase the risk of STIs and does not lead to infertility. For
women who are at a low risk of sexually transmitted infections, such as those who are in
monogamous relationships, the risk of developing pelvic inflammatory disease (PID) with IUC
use is less than 1 in 100 and is even less in women who use LNG-IUS (Mansour, 2012). Women
who use IUC and develop an STI or PID rarely need to have the device removed. Mansour
(2012) found that discontinuation rates due to PID were 0.5 and 2.0 per 100 women at 3 years
(p=.013) for the LNG-IUS and copper IUD, respectively, and 0.8 and 2.2 per 100 women (p<.05),
respectively, at 5 years. When a woman develops an STI or PID, she should be treated with
antibiotics right away. The IUC can remain in place if symptoms improve within 72 hours. If
symptoms persist, the IUC should be removed (Hatcher et al., 2011).
IUC does not increase the risk of ectopic pregnancy, regardless of whether a woman has
had a prior ectopic pregnancy. Ectopic pregnancy occurs 10 times more frequently in women
11
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who do not use contraceptives than in IUC users. Mansour (2012) found that ectopic pregnancy
rates were 0.045 and 0.22 per 100 LNG-IUS users at 1 and 5 years, respectively. For women
who did not use any contraception, an estimated rate was 1.4 per 100 pregnancies. The U.S.
MEC found no restriction to use for patients with history of ectopic pregnancy (US MEC, 2010).
Mansour (2012) also found no significant abnormal cytopathological effects on the LNGIUS users in a 7-year long-term study of cervical smear samples. Progestin-releasing intrauterine
contraception has been shown to reduce the incidence of endometrial cancer because it is more
effective in reducing endometrial hyperplasia than oral progestin, and the LNG-IUS also
prevents endometrial polyps in women taking tamoxifen for up to 4.5 years (Hatcher et al., 2011;
Mansour, 2012). The copper IUC’s mechanism of action is unclear, but the endometrium
alterations may be related to the presence of copper; (Hatcher et al., 2011) therefore, both types
of IUCs may reduce the risk of endometrial cancer (Hatcher et al., 2011; Mansour, 2012).
Literature Review
The currently used intrauterine devices are very safe and more effective than other types
of contraceptives (Secura et al., 2010). IUC efficacy is similar to sterilization at 99%, but fertility
can be reversed rapidly after the device’s removal. An IUC can be used by both parous or
nulliparous adolescent women (ACOG, 2007). However, it is currently underused among
adolescents who are in the high risk group for unintended pregnancies, and this is largely due to
a lack of knowledge regarding IUC. Furthermore, clinical providers are often reluctant to
provide IUC services due to historical problems with outmoded devices, ongoing misconceptions,
and lack of training.
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A literature review was conducted to evaluate the effectiveness, acceptability, and
continued use of these highly effective contraceptive methods by the young female population.
Due to scarce data on long-acting reversible contraceptive (LARC) use among the adolescent
group, it is important to determine whether LARCs are acceptable among this age group.
Mestad et al. (2011) conducted a longitudinal, observational study in St. Louis, MO -- the
Contraceptive CHOICE Project -- to promote LARC with no financial barriers and to evaluate
use, satisfaction and comparison of continuation between LARC and non-LARC methods. The
LNG-IUS, Copper IUD, and subdermal implant are included among LARC methods. Combined
and progestin-only oral contraceptives, depot medroxyprogesterone acetate, the vaginal
contraceptive ring, the transdermal contraceptive patch, and barrier methods are included in the
non-LARC methods.

There were 5086 female residents of St. Louis participants, aged 14-45

years, who were evaluated for their contraceptive method preferences by age. All methods of
reversible contraception were offered without cost to women for 3 years. This study objective
was to estimate the association of age and preference for LARC or other methods, and preference
for specific LARC method among adolescents aged 14-20 years. LARC methods were chosen
by 70% (n=3557) of study participants, but among the adolescents age 14-20 years, 62%
(658/1054) chose a LARC method. Among 14-17-year-olds, 69% (148/214) chose a LARC
method, whereas 61% (510/840) of 18-20-year-olds chose a LARC. Of the LARC methods, a
subcutaneous implant was preferred among the 14-17 year olds (63% or 93/148); however,
selection of a subcutaneous implant device was only 29% (146/510) among 18-20-year-olds.
This study concluded that LARCs are acceptable among adolescents enrolled in this project and
the implant was the most popular method among the younger group.
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Fanarjian, Drostin, Garrett, & Montalvo (2012) conducted a retrospective cohort study to
evaluate the effectiveness of free intrauterine contraceptives in reducing pregnancy rates among
low-income women. The study, conducted in two North Carolina clinics between January 1,
2003 and June 30, 2009, included eligible uninsured women ages 15-44 years who desired
contraception. Pregnancy rates were studied between groups with the exposure (IUC users) and
the unexposed group (non-IUC users). Non-IUC users included women who chose to use other
forms of contraception or no contraception at all. The original sample size was 321 women;
however, over the course of the 6.5 year study all but 90 were lost to follow up by either phone
or mail. A Levonorgestrel IUC was used in 65 participants; 25 non-users comprised the control
group. Seven pregnancies (11%) occurred in the user group; the IUC had been removed prior to
pregnancy in all 7 subjects. Of the 7 pregnancies in the user group, 3 were planned. Eight
pregnancies (8/25 or 32%) occurred in the non-IUC users. Even though a small study sample
due to the low response rate (32%) was the main restriction of the study, the final result showed
no pregnancy per 100 women years in the IUC user group compared to 16.2 pregnancies per 100
women for the unexposed group.
Godfrey and colleagues (2010) investigated the effectiveness of LARCs in a multicenter,
randomized, controlled pilot study (n=23) of 14-18-year-old females divided into groups who
were randomized to receive a copper T 380A IUD or LNG-IUS. At 6 months of follow up, the
continuation rate for the levonorgestrel group was 75% compared with 45% for the copper T
380A group (p = .15). Among those participants at 6 months, 100% in the LNG-IUS group and
83% in Copper T380A group planned to continue their IUC use after the study (p=.36). Both
methods were rated favorably by study participants, but there was a non-statistically significant
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lower continuation rate at 6-month follow up among the copper T 380A users. The pilot study
results warrant a larger scale study of IUD use among adolescents in the future.
Short, Dallay, Omokanye, Hanisch, & Inki (2012) published an interim analysis report at
the end of the first year of an observational study regarding the acceptability of levonorgestrel
IUS (LNG-IUS) and etonogestrel implant (ENG implant) use among young European women,
ages 20–35 years. The study included 454 women from 4 countries (France, Ireland, Slovakia,
and the United Kingdom) who opted to switch from oral contraception to either the LNG-IUS or
the ENG implant. At the planned interim analysis in September 2010, follow-up data had been
obtained from 311 women out of the original 454. Among 311 study subjects, there were 211 in
the LNG-IUS group and 100 in the ENG implant group. The continuation rates at 12-months
were 93% for LNG-IUS and 86% for ENG implant. At 1-year follow up, there were no
pregnancies, pelvic inflammatory disease, perforations, or other complications recorded.
Participants’ satisfaction was evaluated with a 5-degree Likert-like scale at the 12-month followup visit or at discontinuation. About 62% of LNG-IUS users were satisfied with their
contraceptive method compared to 36% of the ENG implant users. The difference in level of
overall satisfaction between the two groups was statistically significant (p<0.001). Most users
were satisfied with their method of contraception after 1-year of follow-up. The conclusion of
the study showed that both the LNG-IUS and ENG implant are highly acceptable contraceptives
among women, but the LNG-IUS users showed the highest continuation and satisfaction rates.
A systematic review of the literature regarding IUD use among adolescents was
conducted by Deans and Grimes (2009). Six cohort studies and seven case-series were included,
but none of the IUDs included in the study are currently in use in the United States. Generally,
the IUD has similar or better continuation rates when compared with combined oral
15
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contraceptives. The cumulative pregnancy rate among IUD users was low, ranging from 2% at 6
months to 11% at 48 months. Even though the published studies show improved rates of IUC
use in adolescents, the literature on IUC use among adolescents is sparse. Further randomized
control trials and cohort studies are needed.
Mansour (2012) also provided updated information of the risk and benefits associated
with use of levonorgestrel IUS through a literature review. Rapid fertility return after
discontinued use is well established. Even though transient menstrual disturbances during the
first few months of use is typical, the condition will generally resolve itself with continuing use
and the total amount of menstrual blood loss will also decrease. Available data from the
literature does not show adverse effects on bone health, cardiovascular events, breast, or uterine
cancers, and it can be used by a wide range of populations.
Overall, research demonstrates that IUCs are acceptable, safe, highly effective, and nonuser dependent. The evidence strongly supports the integration of IUC services into primarycare services, and student health clinics are ideal locations for the provision of IUC services.
Evidence-Based Practice
Evidence-based practice involves the usage of quality studies as evidence to prevent
errors in information, which will contribute to better clinical practice and quality patient care. In
order to identify the strengths and weaknesses of a research article and validate its findings, the
critical appraisal process of a research study must be used to find the most relevant, high-quality
studies (Young & Solomon, 2009). In this project, the project leader independently completed
the literature review process, which may lead to possible bias such as information selection
bias. The STROBE (Strengthening the Reporting Observational Studies in
16
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Epidemiology) criteria was used to evaluate observational studies, including cohort, case-control
and cross-sectional studies (Young & Solomon, 2009) in hopes of assessing study quality and
lessening study selection bias (Sanderson et al., 2007; von Elm et al., 2007) (see table 1 & 2 on
page 85-89).
Conceptual/Theoretical Framework
Since the 1960s when the nurse practitioner (NP) role was developed, NPs have become
increasingly important to serving as primary care providers who provide comprehensive services
including health promotion, disease prevention, and counseling. The 2010 Institute of Medicine
(IOM) report The Future of Nursing: Leading Change, Advancing Health recommended that
nurses should be providing health care services as fully as they were trained in their educational
programs (IOM, 2011). Following the implementation of the Affordable Care Act in 2010, more
than 16 million individuals are projected to gain health insurance coverage by 2016. Combined
with the rapidly aging population, NPs are increasing in demand as primary care providers. An
up-to-date literature review of NP practices by the National Governors Association (NGA) found
that the quality of care provided by an NP and resultant patient health outcomes, is comparable
to care provided by a physician (Schiff, 2012).
NPs can serve successfully as primary care providers and can be differentiated from
physician’s services as human caring is being blended into NPs scientific-based training and
clinical practices (Hagedorn & Quinn, 2004). Human Caring is depicted by the Chinese
characters “關心”, and this topic was discussed in an article by Jean Watson during in 1970s.
Human caring is essential in nursing practice, and this concept empowers nurses to ensure
patient safety and better patient health outcomes. The core concepts of Watson’s theory of

17

Adding LARC Services into Student Health

human caring/caring science is derived from carative to caritas that was assembled and published
by the Watson Caring Institute (2010). Her carative factors are the basis for current nursing
practices. Watson’s human caring theory, such as caritas processes, also called caring practices,
have been applied into daily clinical practice. For example, human caring for others and for self
is the first core concept that is based on the moral, ethical, and philosophical foundation of love
and values. Respect for the person, including clinical staff and patients, and commitment to
protecting human dignity are all aspects of care provided to meet their needs, routines, and
rituals. Increasing awareness of presence to the humanism of self and others and caring for self,
others, and environment are also core concepts of Watson’s human caring theory.
As primary care providers, NPs meet the complex challenges of translating rapidly
expanding knowledge into practice and function in a changing health care environment. The NP
Core Competencies emphasize independent and inter-professional practice, analytic skills for
evaluating and providing evidence-based, patient centered care across settings, and advanced
knowledge of the health care delivery system (NONPF, 2012). The human caring theory is also
essential for practice NPs to provide quality patient care, ensure patient safety, and empower
patients to make informed decisions about their care. This will improve patient’s self-care and
health outcomes, and care for the environment.
Methods
Ethical issues
As a health care provider with ethical obligations, one of the trademarks of
professionalism is the responsibility to respect the clients’ interests above all else. After
reviewing the Belmont Reports, established in 1979 by the National Commission for the
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Protection of Human Subjects of Biomedical and Behavioral Research, the three general ethical
principles, identified to the ethical conduct of research with humans, are also essential in daily
clinical practice.

The first ethical principle is “Respect for persons,” the concept that a client’s

autonomy must be acknowledged and each individual should participate in informed decisionmaking of their own care. The second principle is “Beneficence,” or “Do no harm,” meaning
that providers should make decisions in order to maximize benefits while minimizing possible
risks. The third, “Justice,” requires that the patient is treated fairly, equally, and appropriately
(Beauchamp & Childress, 2009). These three general principles establish the foundation for the
conduct of research; similarly, clinical practice principles are guided by informed consent,
risk/benefits assessment, and care provided fairly.
This quality improvement (QI) project for adding LARC services into primary carefocused student health is based on the observational study of the current clinical services of
women’s health care and contraceptive use by current students. Prior to initiation of this project,
the project proposal was approved by the DNP Department and Institutional Review Board
approval (Appendix A-1 & A-2) was completed to ensure patients’ safety & privacy.
Contraceptive use was evaluated by retrospective chart review from all women’s health related
clinical visits without involving any demographic data of individual student identities to ensure
patients’ privacy. LARC protocol and informed consent have been completed and approved by
the administrative committee as well as all providers to ensure patient’s safety in receiving
LARC services.
Also, addressing the misperceptions regarding the use of IUC among patients and health
providers can facilitate smooth integration of IUC services into a primary care focused student
health clinic. The U.S. MEC is an essential tool that is useful to health care providers in the
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clinic to counsel female patients and couples on safe choices for contraceptive methods and to
assist women with medical conditions understand their choices for contraception (U.S. MEC,
2010). Informed decisions made by patients in clinical practice will lead to better patient selfcare and health outcomes. A consultation appointment to explain the mechanisms of the LARCs
along with obtaining informed consent (see Appendix B) is essential to help patients & partners
dispel their fears & misconceptions about the methods that they decide on.
Setting
Student Health and Counseling Services (SHCS) of California State University, East Bay
(CSUEB) is an on-campus outpatient clinic accredited by the Accreditation Association of
Ambulatory Health Care, Inc. (AAAHC), which offers mainly primary medical care to students
and is staffed by three full-time and two part-time physicians, one full-time and one part-time
nurse practitioner, two full-time registered nurses, one full-time licensed vocational nurse, and
five full-time medical assistants. There are also health promotion and counseling departments
within SHCS that are staffed with many health educators and counselors. There is a staffed
pharmacy and laboratory on site. According to the 2011 Enrollment Headcount Report, there
were 13,160 enrolled students composed of about 60% (7,959) female and 40% (5,201) male
students with an average age of 26 (Baker et al., 2013).
The mission of SHCS is to assist students in achieving their academic and career goals by
providing resources to help them maintain optimal health, to provide high quality, low cost
health care to all CSUEB students, and to be pioneers in the university health and wellness
services.
Planning the intervention
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Market Analysis
To understand the current state of the need to provide LARC service, a SWOT analysis
has been completed (see Appendix C). Based on the SWOT analysis of the strengths of the
project, one skilled staff nurse practitioner is able to consult, insert and follow up with students
who have chosen a LARC method and will help train staff physicians and assist with their first
few procedures. Care is provided on campus at the SHS which is a convenient location for
students. There is no restriction per student on the number of clinical appointments, and students
with concerns who wish to meet with a provider will be able to book the earliest appointment
available by calling in or by self-booking online. LARC methods are fully reimbursed by the
Family Pact Program. The SWOT analysis also point out weaknesses of the project. Concerns
center on the need to train three staff physicians on LARC use and follow up, and the expense of
acquiring LARC devices before providing the service. The third SWOT analysis, opportunities,
indicates that there will be many opportunities to provide LARC services, as none of the other
CSU campuses provide the services, the Planned Parenthood clinics and community health
clinics where students used to be referred are all located off campus, and not all students have
cars to visit clinics off campus. To visit clinics off-campus is very time consuming to students.
Also, staff physicians will gain new skills to serve patients. Finally, to analyze threats to the
project, the cost of each LARC unit is currently approximately $700 dollars. Competition for
services include Planned Parenthood Mar Monte which provides clinic services at their Central
Hayward location, although with restricted hours, and the Community Health Care Network
clinics, Women’s Clinic of Alameda County Medical Center, and private health clinics.
Currently, SHCS does not accept any medical insurance; therefore, students who are interested in
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LARCs and not eligible for coverage by Family Pact program will need to seek care from their
own primary care providers or pay out-of-pocket.
Gantt chart
The Gantt chart depicted in appendix D provides information about LARCs service
project planning and monitors progress for tasks such as training providers, staff, meeting with
the administrative team, and service launch. The Gantt chart is posted on a Google drive file to
share with all staff in the clinic.
Critical Activities
To ensure a safer patient care environment by preventing errors and mitigating the risk of
causing harm to patients and staff, a clinical protocol and policy regarding the LARC procedure
and medical errors also must be established. Prior to starting the LARCs service, the potential
risks of patient adverse outcomes needs to be carefully evaluated and precautions put in place to
ensure the safest patient care at SHCS. The Failure Modes and Effects Analysis (FMEA) or
Failure Modes, Effects, and Criticality Analysis (FMECA) is a systematic, proactive method to
investigate potential risks that focuses on identifying vulnerability and preventing future failures.
FMECA focuses on system design and process rather than on a single incident such as in rootcause analysis (IHI, 2004; Nagamine & Williams, 2005). When doing a FMEA, we should
include a review of the following steps in the process: failure modes (what could go wrong?),
failure causes (why would the failure happen?), and failure effects (what would be the
consequences of each failure?) (IHI, 2004; Larson & Gray, 2011). An example for this project is
shown in Appendix E. Every specific step in the process that can possibly go wrong is listed in
the flowchart with the consensus of the group. All possible causes are identified for each failure
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mode listed. Next, the group is assigned a numeric value (known as the Risk Priority Number, or
RPN) from 1 -10 for likelihood of occurrence, likelihood of detection, and severity. Then,
multiplying the three scores, we obtained the RPN for each failure mode. Therefore, in order to
focus improvement efforts on the most important area of the process, it is helpful to find out the
failure modes with high RPNs.
The activities have been evaluated for potential risks, which were included in a “things to
look for” section during the presentation to the administrative team, and also reviewed while
comprehensively training providers, keeping an updated list of supplies, tools, LARC units, and
establishing an account with pharmaceutical companies for purchasing of LARC units. An
informed consent for patients and LARC protocols (appendix B-2 and B-3) are established and
approved for the staff to use. Advertising on campus is via text message, email, through the
SHCS home page, and advertisements sent to other CSU campuses.
Plan for Variance Control and Evaluation Criteria
We use data collection forms (Appendix F) to collect information from scheduled
women’s health related appointments by all providers. To prevent errors and to make it easier to
trace errors for correction, individual providers tally their data on the data collection form each
week. For providers who have missing data, the project leader follows up at the end of each data
collection period. Using data from the summer & fall quarter allow us to gain a perspective from
a mixed student population. For example, there are more junior & senior students in summer
quarter and more freshmen students in the fall quarter.
Evaluation Criteria
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The forms used for data collection were made by the primary investigator based on the
study inclusion criteria derived from the Female Medical History Form that is part of the
recommended documentation by the Family Pact Program: age, history of pregnancy, sexual
partners, method of contraceptive use, and length of usage (Family Pact, 2014).
Before providing new medical services in the primary care clinic according to affordable
care act (ACA) expectations, the primary care providers and internists must attend new training
workshops. County or local specialists contact information has been updated for consultation or
referral as needed. Annual refresher courses will be planned as needed depending on the amount
of services provided.
Risks Prevention
A risk breakdown structure (RBS) (appendix G) is used to help identify risks from the
macrosystem to microsystem that affect adding the new service in order to mitigate risks and
prevent adverse events in advance (Larson, 2011). The risks can be identified in four categories:
technical, external, organizational, and project management. The subcategories under technical
risk include skills for the procedure, reliability and quality of the service. The external risks
include regulatory, policy and procedure, market, and customer. Resources, funding and
prioritization are considered under the category of organization. For project management,
estimating, planning, control, and communication are considered.
Institutional Review Board (IRB) training and completion (see appendix H) is required
by the Project leader to ensure human subject protection and to minimize risks from the study.
No patients’ identities are included in the data processing or reports.
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An Ishikawa diagram (Appendix I) is used to help plan the project and identify potential
risks that will affect the project (Nelson, Batalden, & Godfrey, 2007). The diagram also is used
for continuing evaluation of the project as it progresses, and updates will be provided and
discussed during the weekly provider/staff meeting and monthly QI meeting.
Implementation of the project
A retrospective review of electronic records from approximately 1000 clinical notes of
all women’s health related visits during summer & fall quarter from June 24 to December 24,
2013 has been completed. The chart review and data collection was performed from December
2013 through the end of January 2014. A form with the necessary information and key criteria
for study in Appendix F was developed during summer 2013 and was continuously revised
throughout the fall quarter. Data were analyzed by project leader in April 2014.
An advertisement and marketing program is important and needed for this new service,
including but not limited to text messages sent to students and emails broadcasting to other CSU
campuses. The nursing department is responsible for organizing the required supplies and
instruments on the list provided by the Nurse Practitioner who also will continue to update the
list as needed. A meeting with the Clinic Director, the Administrative Analyst for purchasing
LARC units was completed at the beginning of summer quarter 2014. Students who are
interested in LARCs will be required to have a consultation appointment prior to scheduling a
LARC placement appointment, and these consultation appointments may be scheduled anytime
per the student’s request. The service was planned to be provided to students starting summer
quarter 2014, but has been delayed to fall quarter because the procurement process is still
pending and the summer quarter students’ health clinic coverage was changed by the university.
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A list has been established during the spring quarter and summer quarter for students who are
interested in LARC and wished to be contacted when the service is available. On October 20th,
the nurse practitioner received a call from the pharmacist that one of LARC units, the
contraceptive implant, has been approved to start. A secure message was sent to individual
students on the list regarding the approval of the service.
Planning the study of the intervention
Action Plan of LARC Services
On college campuses, Student Health Clinics have the unique role of helping students
maintain their optimal health which allows them to succeed in academic study, future career, and
in life. The majority of enrolled students are females between the ages of 18 and 24, and do not
plan to conceive while they are pursuing their college education (ACHA-NCHA II, 2013).
Preventive health services, including family planning and the provision of highly effective longacting reversible contraception, are essential and should be integrated into primary-care focused
student health clinics. To prepare for the integration of LARC services into primary-care
focused Student Health Clinics, the action plan includes staff education, patient counseling, risk
prevention, administrative issues, and establishment of equipment protocols (clinical minutes,
ARHP, 2013). The goals are to increase access to LARC services, empowering patients,
improving efficiency, and improving staff knowledge.
Staff education: Staff education is essential to integrating LARC services into the college
student health clinics. This means new skills and scientific-based evidence for the primary care
providers and internists who do not specialize in the area of women’s health care. LARC
placement and removal training is the first step. Annual refresher courses to update skills and
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knowledge will be planned as needed depending on the amount of service provided (see Table 4
provider training plan on page 87). The U.S. MEC is an important resource for health care
providers to counsel their patients and to help them make safe choices for contraceptive methods
(US MEC, 2010). Furthermore, nurse practitioners and health care providers also use the U.S.
SPR as guidance for clinical contraceptive management to help reduce the unintended
pregnancies rate among college students (US SPR, 2013).
Patient education: Clinicians are providing individualized counseling for contraception
choices, the efficacy, benefits, and side effects of method chosen (US MEC, 2010; US SPR;
Hathaway, 2013), and utilizing the “Teach-Back” method to assess, teach, and confirm student’s
understanding of the information (AHRQ, 2010; Moritsugu, 2006; Brach et al., 2012; White,
Garbez, Carroll, Brinker, & Howie-Esquivel, 2013). Clinicians must provide time for students to
review and sign the Informed Consent Forms for the LARC procedure.
Risk prevention: Policy and LARC clinical practice protocols have been established to
help plan the services, to identify and mitigate potential risks, and to prevent negative outcomes.
Patient selection criteria and contraindications according to the U.S. MEC for LARC method are
included in LARC clinical protocols. Any patient, whose desired LARC with U.S. MEC 3 and
4 conditions will be excluded, so clinical protocols for consultation or referral to local specialists
have been established. Risks that have been addressed include ensuring that providers have the
necessary skills, that standard of care is maintained, and that appropriate policies and
communication channels are in place if any adverse incidents are to occur.
Administrative issues: The administrative team has addressed the purchase of LARCs
prior to beginning services. In addition, an appointment policy has been developed. On average,
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three appointments (consultation, insertion, and follow up) are needed for each patient. A
consultation appointment will be required from students who are interested in LARC prior to an
LARC placement. Billing and coding training have been completed for reimbursement of LARC
services that included management of costs of all necessary health care services and supplies.
Advertisement and marketing are also important when offering a new service. To spread the
word about services text messages and emails are employed.
Equipment protocol: New instruments exclusively for LARC placement or removal have
been requested and completed. The Nursing Department is responsible for coordinating
equipment inventory, organizing the required supplies, and ordering and restocking LARC
devices. The supplies include: miscellaneous supplies (clean gloves, sterilized gloves, betadine
swab sticks package, sterilized gauze, long big cotton swabs, silver nitrate sticks, Maxi pads, and
patient instruction), instruments (sterilized speculum, ring forceps, tenaculum, uterine sound, and
long scissors), and LARC devices.
LARC service evaluation: The program will be evaluated quarterly. The following
outcomes can be used to measure program progress & success - number of LARC consultations,
number of LARC placements, continued contraception use, training progress, quarterly billing
and reimbursement, and satisfaction of the services from patients and staff. Students will be
followed every 6 months by secure message system within their electronic record or by phone
with electronic documentation until they graduate.
A retrospective evaluation of LARC services to assess the success and long-term
sustainability of the program is necessary. Off campus referral rates, adverse procedure incidents,
infection rates, and staff and provider satisfaction regarding the process must be studied.
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Improvement measures for continuation of the service should be discussed monthly to assure that
the best quality of care is delivered and patient safety is maximized at Student Health Services.
Analysis
According to the ACHA-NCHA II Spring 2013 nationwide survey results, 64.4% of
sexually active college students used hormonal contraceptives including oral contraceptive pills,
patches, and rings; 3.4% received DMPA injection; 1.8% used contraceptive implant; and 6.9%
used IUC. The current usage of LARC among our students, who use a contraceptive method and
have visited SHCS, is 1% for contraceptive implant and 3% for IUC (See Appendix J). LARC
usage by our students is much lower than the national benchmarks (see Table 1), which may be
partially associated with the fact that the LARC services are not available in our SHCS.
Results
Description of Data:
Records from all female university students who visited SHCS during summer and fall
quarter 2013 for women’s health related care were reviewed. All female students in any age,
race, and ethnicity were included. Electronic medical records of all visits and demographic
information were reviewed and analyzed by the primary investigator from February to March
2014. A faculty member in the statistics department was a consultant for the on-campus study in
the summer 2013. A few of the female patients who were seeking care for women’s Health
related issues were under age 18 at the time of study and their parental consents and clinic care
consents for care were on file; otherwise, their records were excluded in this study.
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Evidence of Data Collection: the Primary Investigator conducted a chart review of
clinical visits through the electronic health record (health history, medical record, lab report) at
the beginning of 2014 at SHCS. A data collection form (See Appendix F) that was developed
during the summer quarter was used. For the study, we tracked client data by electronic chart
review based on the clinical visit notes during June 24 to December 20, 2013. A retrospective
review of 1031 subjective notes of all women’s health related visits during summer and fall
quarter from June 24-December 20, 2013 was performed. The chart review and data collection
took place in January-February 2014. A form with the necessary information for study was
developed during summer 2013 has been used to tally the data. Data were analyzed by the
project leader. The analysis was complete in April 2014. (See Appendix J)
Study Results: After reviewing a total of 1031 visits electronically from June-December
2013, the project leader found that most of our clients (71%) were 24 years-old or younger. The
contraceptives used by our clients were: 52% hormonal contraceptives, including oral
contraceptive pills, patches, and rings; 7% DMPA injection; 1% contraceptive implant; and 3%
IUC. (See Appendix J)
Program evaluation/Outcomes
The program will be evaluated at the end of every academic quarter. The following key
performances will be used to measure program progress and success including number of LARC
consultations, number of LARC placements, pregnancy rate, training progress, monthly financial
reports, and satisfaction surveys from patients, providers, and staff. Providers will follow up
with patients every 6 months by secure message system or phone until they graduate. A weekly
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update of project progress will uploaded to a google drive file to share with all providers and the
QI committee, and a monthly report will be given at the all-staff meeting.
By June 30, 2015, a retrospective study for this LARCs service will be held. Besides the
key service performances, the off campus referral rates, adverse procedure incidents, infection
rates, and unintended pregnancy rates will be studied. The final report will be delivered in QI
committee meeting and the first all-staff meeting in the fall quarter. Based on the study results,
the improvement measures for the future service will be started during the weekly provider
meetings during the fall quarter 2015 to assure the best quality of care is delivered and patient
safety is maximized at SHCS.
Discussion
Summary
Compared to the ACHA-NCHA II Spring 2013 nationwide survey results, LARCs usage
by our students is much lower than the national benchmarks, which may be partially accounted
for by the fact that the LARC services are not available in our SHCS.
Potential benefits: The study results will help to guide implementation and
improvement of women’s Health services at SHCS. Because this is based on a retroactive chart
review, no compensation or other incentives will be provided to any of the students.
Potential risks: Privacy and emotional discomfort (unrelated to the direct effects of the
study) may be potential risks that will be felt by some students who visited SHCS during the
time of the study.
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Risk reduction: Any patient’s identifying information will not be used during the data
collection and this helps to minimize the potential risks to any student included in the study.
Risk/Benefit: The potential risks to the subjects, such as privacy and emotional
discomfort felt by some of the students who visited SHCS during the study period were not
related to the direct effects of the study.
Study limitation: The study was conducted for the purpose of quality improvement at
the on campus student health clinic of CSUEB, so the study demographic was limited only to
students registered with CSUEB during the study period. The results will help clinic services
and quality improvement, but further study will be needed to determine the applicability to other
colleges and student health clinics.
Study unexpected benefit: Improvements in clinical documentation for better service &
care to the clinic patient is very important. From the data collected, it was determined that about
14% (143/1031) patients’ past obstetrics, gynecology, and sexual history information were
missing (See study results, p32.). This information is very pertinent history for women who are
seeking contraceptive care. The importance of this data will be emphasized throughout project
implementation and improvements tracked.
Barriers to implementation/Limitations: Adding new patient services means that
clinic providers must learn new skills or be able to perform a skill that they may not comfortable
or familiar with. All of the providers in our clinic graduated from their medical schools or nurse
practitioner programs over 15 – 20 years ago. For seasoned clinical providers, learning new
clinical skills can be a challenge, and the many misconceptions about LARC use and the
notorious history of the Dalkon Shield IUD about 30 years ago are keeping both patients and
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providers at a distance. Despite the safety and efficacy of modern LARC devices, dispelling
misconceptions and rumors, training providers and staff, patient counseling and informed
decision making with evidence-based information are all barriers that must be addressed prior to
the effective integration of LARC services into primary care-focused student health clinics.
Conclusions
Unintended pregnancy is still a significant social issue that affects the quality of life for
parents and their children. Since the highest rates of unintended pregnancy occur in college age
women, and about 80% of college women are sexually active without planning to become
pregnant (Kavanaugh et al., 2012), it is very important to provide these women with effective
contraceptive methods. To help prevent unintended pregnancies, integrating LARC services into
primary care-focused health clinics and student health services is necessary. Provider training
and patient counseling to dispel misconceptions regarding LARC use has been shown to improve
usage and continuation rates of LARC contraception (Arrowsmith et al., 2012; Garber et al.,
2013). To help young college aged women make an informed decision about contraception use,
Nurse Practitioners and Medical Providers need to eliminate the misconceptions and provide
evidence-based information to educate adolescents and young women about LARC methods and
access. All of these steps will help reduce unintended pregnancy, help to increase contraceptive
use and adherence, promote healthy behaviors, decrease sexually transmitted infections, and
increase access to the health care system.
Other information: Provider Training and Funding
Provider training
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This project was received very enthusiastically by the Student Health Center. All full
time and part time providers have attended the Nexplanon training session by Pharmaceutical
company and have received Nexplanon certification. All full time providers have also received
training for Mirena insertion and removal. 1 Family Practice physician and 1 internist have
completed training of Paraguard IUD, and they will continue onto the next steps of training –
observation, supervised insertion, and supervised removal of all LARC devices. Future training
sessions for the remaining providers will be scheduled based on their availability (see Table 4
Provider LARC training plan on page 87).
Budget presentation
Direct costs for this project include providers, equipment, and supplies. Providers include
one nurse practitioner (1FTE), three physicians (3 FTEs), two part-time physicians (total of 0.4
FTE), 7 FTEs of supporting staff including two registered nurses, and five medical assistants.
The supply costs will cover miscellaneous supplies (clean gloves, sterilized gloves, Betadine 3swab package, 2x2 sterilized gauze, 3 ml syringe, injection needles, 1% Xylocaine injection
solution, long cotton swabs, Maxipads, instruction handouts), tools (5 of each—sterilized
speculum, ring forceps, long kelly clamp, tenaculums, metal or plastic sounds, long scissors),
and starter LARC units ( 5 of each ENG-Implant, Copper T 380A IUD, and LNG-IUS). Indirect
costs include 1 FTE center director, 2 FTEs administrative assistants, 4 FTEs front desk staff, 1
FTE IT staff, 1 FTE housekeeping, 1 FTE health promotion staff, educational and advertising
material, computer, office, etc.
A pre-paid package includes a total of fifteen LARCs units, or five of each type, which will
costs about $11,000 plus $2,000 of supplies, for a total of $13,000. On average, three
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appointments will be needed for each patient including one 30-min LARCs consultation, one 30min LARC placement, and a 15-min appointment for 2-month follow up after LARC placement.
The medical assistant needs about15 minutes to set up the exam room and intake the patient. A
male provider will require a chaperone while performing the pelvic examination or procedure.
The cost of providing the LARC services to students at SHCS will be reimbursed by the
Family Pact Program. After consulting with the providers and staff at SHCS, all parties believe
that providing this service is feasible and will be beneficial for both students and SHCS. The
funding for a few LARC units and the initial set-up are required in order to start the service.
Budget projection for the pre-paid LARC units and reimbursement are estimated and outlined in
Appendix K-1. Since the Implant Contraceptive has been approved to purchase in October 2014,
a budget projection for Implant Contraceptive service is estimated in Appendix K-2.
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Appendix B-1. LARC Informed Consent
STUDENT HEALTH & COUNSELING SERVICES
California State University, East Bay
Hayward, California 94542-3060
Informed Consent For NEXPLANON Placement or Removal
A. Consent For Procedure(s)
I authorize ______________________________________,MD/NP to perform the following procedure(s):
NEXPLANON (etonogestrel implant) Radiopaque Subdermal Use Only
I have read and understand the Patient Information for NEXPLANON. I have discussed NEXPLANON
with my healthcare provider who answered all my questions. I understand that there are benefits as well
as risks with using NEXPLANON. I understand that there are other birth control methods and that each
has its own benefits and risks.
I also understand that this Patient Consent Form is important. I understand that I need to sign this form to
show that I am making an informed and careful decision to use NEXPLANON, and that I have read and
understand the following points.


NEXPLANON helps to keep me from getting pregnant.



No contraceptive method is 100% effective, including NEXPLANON.



NEXPLANON has an implant that contains a hormone.



It is important to have the NEXPLANON implant placed in my arm at the right time of my
menstrual cycle.



After the implant is placed in my arm, I should check that it is in place by gently pressing
my fingertips over the skin where the implant was placed. I should be able to feel the
implant.



The implant must be removed at the end of three years. The implant can be removed sooner if I
want.



If I have trouble finding a healthcare provider to remove the implant, I can call 1-877-467-5266
for help.



The implant is placed under the skin of my arm during a procedure done in my healthcare
provider’s office. There is a slight risk of getting a scar or an infection from this procedure.



Removal is usually a minor procedure. Sometimes, removal may be more difficult. Special
procedures, including surgery in the hospital, may be needed. Difficult removals may cause
pain and scarring and may result in injury to nerves and blood vessels. If the implant is not
removed, its effects may continue.



Most women have changes in their menstrual bleeding patterns while using
NEXPLANON. I also will likely have changes in my menstrual bleeding pattern while
48

Adding LARC Services into Student Health
using NEXPLANON. My bleeding may be irregular, lighter or heavier, or my bleeding
may completely stop. If I think I am pregnant, I should contact my healthcare provider as
soon as possible.


I understand the warning signs for problems with NEXPLANON. I should seek medical
attention if any warning signs appear.



I should tell all my healthcare providers that I am using NEXPLANON.



I need to have a medical checkup regularly and at any time I am having problems.



NEXPLANON does not protect me from HIV infection (AIDS) or any other sexually
transmitted diseases. After learning about NEXPLANON, I choose to use NEXPLANON.

B. Consent For Anesthesia
When local anesthesia is used for NEXPLANON placement or removal by the MD/NP on page one,
Section A:
I consent to the administration of such local anesthesia, 1% LIDOCAINE without Epinephrine as may
be considered necessary by the MD/NP in charge of my care. I understand that the risks of local
anesthesia include: local discomfort, swelling, bruising, allergic reaction to medications, and seizures.
C. Patient Signature:
After learning about NEXPLANON, I choose to use or remove a NEXPLANON on my right/left upper
arm. By signing below I state that I have read or had explained to me the contents of this form and I
agree to receive the care, treatment or service listed on this consent. I have had a chance to ask questions
and all of my questions have been answered.

(Name of patient)

(Patient Signature)

(Student ID)

(Date)

D. Physician or Nurse Practitioner Statement/Signature & Witness Signature:
I have explained the procedure(s) stated on this form, including the possible risks, complications,
alternative treatments (including non-treatment) and anticipated results to the patient and/or her
representative. The patient and/or their representative has communicated to me that they understand the
contents of this form. The patient above has signed this consent in my presence after I counseled her and
answered her questions.

(Signature of MD or NP)

(Signature of Witness)

(Date & Time)

(Date & Time)
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Appendix B-2 Protocols
STUDENT HEALTH & COUNSELING SERVICES
California State University, East Bay
Hayward, California 94542-3060

Protocol For Contraceptive Implant (Nexplanon)
Definition:
The ENG-Implant is a thin rod 4 cm long and 2 mm in diameter and contains 68 mg
etonogestrel that is placed in the subdermal tissue of the inner upper non-dominant arm. The
ENG-Implant provides effective contraception, decreases menstrual blood loss, and painful
menstrual cycles for at least 3 years. The effectiveness of ENG implant to prevent pregnancy is
greater than 99%.9,10 The mechanisms for contraception are changing endometrium tissue and
changing cervical mucus to prevent fertilization.
Many women prefer the convenience and efficacy of implantable progestin-only method. A
woman who experiences unacceptable estrogen-related side effects or who has contraindications
to estrogen-containing contraceptive methods may be to use progestin-only birth control methods
successfully. Progestin-only methods may be preferred to combination hormonal methods for
women with chloasma, hypertension, VTE, severe headaches, chronic asymptomatic hepatic
disease, breastfeeding, tobacco use and age > 35 with a BMI greater than 30. The typical use
first year failure rates for progestin-only implants are at least as low as sterilization and with
correct and consistent use may be as low as 0.1% and are not affected by obesity. Progestin-only
implants are often more popular among adolescent women. It is likely that all progestin-only
methods reduce the risk of endometrial cancer, especially in anovulatory women. Several
studies have reported that structured counseling, especially about longer acting methods may be
very useful in helping women choose more effective methods and maximize continuation rates.
Personnel:
Subjective:
Must include:
1. LNMP and PMP.
2. Medical, sexual and contraceptive history (initial or update).
3. Evaluation for allergies to any component of the method or to antiseptic or
local anesthesia, if considering implant.
4. History of any recent unprotected intercourse.
Must exclude:

Any US MEC Category 4 and 3 conditions for her desired method.
Note: Breastfeeding women can initiate any systemic progestin-only method
immediately postpartum, despite labeling recommendations, as long as the women
can tolerate a slight increase in lochial blood loss. There is no increase in
postpartum depression due to progestin-only methods.
Objective:
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Must include:
1. BP.
2. Weight, BMI (obesity is not a contraindication to any progestin-only method.
The efficacy of implants and injections is not affected by patient weight.)
Note: Progestin-only methods may be initiated or restarted without pelvic
examination in asymptomatic women who have not had recent exams. Routine STI
testing may be performed using urine or self vaginal swab specimens, if indicated.
Laboratory:
Must include:
Negative sensitive urine pregnancy test (UCG) only if patient has unexplained
irregular or delayed menses or symptoms of pregnancy. Routine pregnancy testing
is unwarranted. There may be more need to document that pregnancy has been
ruled out for implant candidate seeking placement at unconventional times.
Assessment:
Candidate for systemic progestin-only hormonal method.
Plan:
1. Refer patient if any US MEC category 3 and 4 conditions for desired method.
2. If implant selected, place only if confident patient is not pregnant:
a. No backup method is needed if implant placed at any of the following times:
1) During first 5 days of menses.
2) At any time if switching from combined hormonal contraception,
include hormone free intervals of COCs, patch, or vaginal ring.
3) At any time if switching immediately from progestin-only method,
including progestin-only pills, DMPA injection, LNG-IUD or implant.
4) If exclusively breastfeeding, and amenorrheic in the first 6 months
following delivery, may place immediately if no recent unprotected
intercourse.
5) Within 5 days of first trimester pregnancy loss.
6) Within 28 days after second or third trimester pregnancy loss or
delivery.
b. If placing at any other time, confirm pregnancy test negative, provide EC, if
needed, and advise abstinence or provide barrier method for 7 days after
implant placement.
c. If placing this visit:
1) Explain risks and benefits of implants. Counsel about bleeding changes
that may be expected.
2) Obtain informed consent using SHCS consent form for implant
contraceptive (Nexplanon) that includes all the information found in
FDA-approved form.
3) Place implant according to manufacturer’s instructions.
4) Verify placement of implant.
5) Provide post-placement instructions and precautions. Advise abstinence
or back-up contraception for 7 days, if needed.
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6) Document a placement procedure note.
d. Have patient return for annual examination and PRN problems.
Patient Education:
1. Remind the patient that this method of contraception is safer for her health than
pregnancy would be.
2. Advise women that progestin-only methods do not protect against STIs,
including HIV. Recommend safer sex practices if patient is at risk for STIs.
3. For Implant:
a. Inform patient that she should:
1) Keep the pressure dressing on for 24 hours.
2) The steri-strips can be taken off in 3-5 days, although it is better to wait
until they fall off by themselves. Steri-strips should not be removed by
patient until scab over the placement site had fallen off.
3) If her arm is sore, she may also take Tylenol or Ibuprofen for the
discomfort or place ice packs (20 minutes an hour) as needed.
b. Advise patient to expect slight bruising and soreness around implant site for
a few days after placement, and that the implant may be slightly visible
after healing.
c. Advise patient to watch for these rare warning signs and seek medical care
promptly if any of the following appears:
1) Bleeding from the placement site.
2) Increasing tenderness, redness, warmth or pus around the implant.
3) Fever, chills.
4) Any sign that the implant is being expelled.
d. Advise patient that protection from pregnancy begins immediately if
placement is timed according to manufacturer’s recommendation.
Otherwise she should not rely on the implant for 7 days after placement.
e. Advise patient that bleeding may be less predictable with implant use.
Over time, she will usually have less bleeding.
1) Counsel her that if her bleeding is acceptable in the first 3 months, she
can expect that following cycles will be acceptable.
2) If her first 3 cycles are abnormal, tell her that she has a 50% chance that
her bleeding will improve in subsequent months. The time between
periods may vary and she may have spotting in between periods.
3) Suggest she keep a menstrual calendar and carry a light day panty liner
with her.
f. Remind her to use back up methods if she starts using any St. John’s Wort
or prescription drugs that can reduce the effectiveness of her implant.
g. Counsel patient that there is no harm to her health if she misses her periods,
but instruct her to return for pregnancy testing if she has any symptoms of
pregnancy or is concerned about the possibility of pregnancy.
h. Advise patient of possible weight changes and other potential side effects
including headache, mood swings, hair changes, prolonged ovarian cysts
and other effects listed on package insert.
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i.
j.

k.
l.
m.

1) Remind her that most of those “side effects” are not due to the implant.
For example, in a trial comparing the implant with non-hormonal IUD,
both groups of women gained the same amount of weight.
Advise her to always mention her implant whenever she is seen by medical
personnel/clinician.
Remind her that the implant is effective for 3 years. Tell her she will be
given a user card that will remind her of this date. Remind her that she is to
keep the card in a secure place. Advise patient that a new implant may be
placed in 3 years if desired.
Counsel her that fertility returns promptly after removal of her implant.
Advise patient that she may request to have her implant removed at any
time for any reason.
Encourage patient to return for routine well woman exams.

Referral:
1. Any patient with US MEC category 3 and 4 conditions for this method she
desires to use.
2. Patient who declines pelvic examination but has symptoms or signs indicating
need for evaluation.
3. Patient with a difficult implant removal.
4. Patient with anaphylactic shock with the procedure.
Reference:
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Attachment:
Summary of recommendation for Implant method initiation and management

Initiating Implant Use

Number of Days Back-up
Method or abstinence
Needed

EC Need If Any
Unprotected Coitus in Last
5 days*

Starting cycle day 1 – 5
During hormone free
interval of OCs, patch or
vaginal ring
At any time with progestinonly pills
At time next DMPA
injection is due (up to 15
weeks from last injection)
At time of implant or IUD
removal
Within 5 days of first
trimester pregnancy loss
Within 28 days after 2nd
trimester pregnancy loss
Within 28 days after 3rd
trimester delivery
Exclusively breastfeeding in
the first six months and
amenorrheic with no
unprotected intercourse
Placement at any other time

0

No

0

No

0

No

0

No

0

No

7

Yes

7

Yes

0

No

7

Yes



If unprotected intercourse in last 5 days, consider repeat pregnancy test in 3
weeks if no menses.
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Supplies for the implant procedure
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Appendix B-3: Protocol
STUDENT HEALTH & COUNSELING SERVICES
California State University, East Bay
Hayward, California 94542-3060

Protocol For Intrauterine Device (IUD)
Definition:
Intrauterine contraceptive (IUC) is a small device placed in the uterus to prevent
pregnancy. Currently there are three FDA approved intrauterine devices (IUDs) available in the
US. The Copper T-380A IUD (ParaGard®) is effective for at least 10 years. In typical use, the
copper IUD has a first year failure rate of 0.8%; its 10 years cumulative failure rate is 2.7%.
The Levonogestrel intrauterine systems (LNG-IUS)–20 mcg/24 hr ( Mirena® ) is effective for 5
years and has a first year and 5 year failure rate in typical use of less than 1%. Mirena offers
many non-contraceptive health benefits related to menstrual suppression. The LNG-IUS-13.5
mg (Skyla®) is approved for up to 3 years of use. First year failure rate is 0.41%. IUDs may be
used by nulliparous women.
Personnel:
Physician and Nurse Practitioner/Certified Nurse Midwife with demonstrated skill under
supervision of experienced clinician and/or experience with IUD insertion and removal can place
or remove IUDs.
Identification of Candidate:
The U.S. Medical Eligibility Criteria (US MEC) are used as a basis for recommendations
for this protocol.
Subjective:
Must include:
1. LNMP and PMP.
2. Document any unprotected coitus in last 5 days.
Must exclude:

Any US MEC Category 4 and 3 conditions for her desired IUD.
Objective:
Must include:
1. Normal pelvic exam (Bimanual and speculum exams).
2. Complete uterine involution (after 6 weeks postpartum) is needed following
pregnancy.
3. Patient’s uterine size on bimanual exam must be consistent with a uterine depth
of:
a. ParaGard: 6.0-9.0 cm.
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b. Mirena: 6.0-10 cm.
c. Skyla: large enough to accommodate IUD, generally 6-10cm best.
Must exclude:
 Any US MEC Category 4 and 3 conditions for her desired IUD.
Laboratory:
Must include:
1. Hgb/Hct if recent history of excessive menstrual blood loss or anemia.
2. Patient does not need any testing done to qualify for IUD if she has no signs or
symptoms of infection. If indicated by age, screening guidelines, sexual history
or symptoms, perform needed tests to rule out GC or Chlamydia cervicitis or
Trichomonas vaginitis. It is not necessary to delay IUD placement until results
are available. Prompt (within 7 days) treatment will prevent PID if the woman
does have a cervical infection at the time of IUD placement.
3. Negative pregnancy test if patient has had any unprotected intercourse at any
time in her cycle that could result in pregnancy, or if she has had any irregular
menses recently or any symptoms of pregnancy.
Must exclude:
 Any US MEC Category 4 and 3 conditions for her desired IUD.
Assessment: Candidate for IUC/IUD use.
Plan:
3. Select IUD. If patient has copper allergy, Wilson’s disease, anemia (Hgb less
than 10 g/dL), excessive menstrual bleeding or severe dysmenorrhea, she is a
better candidate for a LNG-IUS rather than for the copper IUD. If she prefers
monthly bleeding or does not want to use hormones, ParaGard® would be a
better choice.
4. Instruct patient to read and answer all questions on patient product information
brochure. Answer all of patient’s questions. Have her sign the manufacturer’s
consent form and any clinic consent form required. See manufacturer’s website
to get additional copies of the patient brochure and the consent forms in her
language. Tell the woman who wants to use one of the LNG-IUSs that she will
have to sign another copy of the consent form for her particular IUS after the
procedure is done.
5. Consider advising patient to take a nonsteroidal anti-inflammatory agent 1 to 4
hours prior to IUD/IUS placement if not medically contraindicated. It will not
reduce pain during IUD placement, but may reduce cramping and pain
afterwards.
6. If possible, place the IUD at this visit (See IUD Placement protocol). If IUD not
placed during this visit, insure she has an interim birth control method and tell
patient when to return for placement according to the type of IUD she desires.
7. Schedule Copper IUD (ParaGard®) placement any time in the cycle when the
woman is not pregnant.
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a. Placement after completion of menses may reduce early expulsion risk. If
possible, avoid placing IUD during heavy menstrual flow days.
b. Copper IUD is effective as post-coital emergency contraceptive for up to 7
days after exposure.
c. May place a new IUD (copper or hormonal one) immediately after removing
an existing IUD, if she is a candidate for her desired new IUD.
d. Postpartum women will wait for an IUD placement until uterine involution
is complete (usually 6-8 weeks).
8. Schedule a levonorgestrel IUS (Mirena or Skyla®) placement according to the
following instructions for on-label placement:
a. Within first 7 days of cycle. To reduce early expulsion rates, try to avoid
placement on heavy flow days.
b. Women who are not cycling (e.g. due to breast-feeding or DMPA-induced
amenorrhea) may have placement at any time they are not pregnant and
have not had recent unprotected intercourse. Advise 7 days use of
abstinence or back-up method after IUS placement.
c. Women switching from OCs, advise completion of pill pack, especially if
IUS is placed during the last week of active pills.
d. May place new IUS immediately after removal of existing IUS if she is still
a candidate. Removal is recommended on menses but if removed at other
time in cycle, advise 7 days of abstinence or use of a backup method
following replacement. Consider EC if she has had recent intercourse.
Neither LNG-IUS is a post coital contraceptive.
e. Placement of an IUS for postpartum women should probably be after uterine
involution is complete (usually 6-8 weeks).
f. If placement is desired at any other time in cycle or under different
conditions, make sure the patient is not pregnant and have her use
abstinence or a back-up method for 7 days following IUS placement.

Patient Education:
1. Reinforce IUD education as described in manufacturer’s brochure. Provide
information about mechanisms of IUD/IUS action, stress the importance of safer
sex practices, describe possible placement complications, and schedule follow-up
as needed if problems arise after placement. Reassure patient that as an ongoing
method, all IUDs work as contraceptives by preventing fertilization.
2. Discuss risks of IUD/IUS if pregnancy occurs: ectopic pregnancy; preterm labor;
need for IUD removal if possible; intrauterine levonorgestrel exposure (Mirena
and Skyla®).
3. Inform patient that Mirena is the most effective medical treatment for heavy
menstrual bleeding, can reduce symptoms of endometriosis and problems with
anemia. By providing progestin, Mirena® also helps reduce the risk of
endometrial cancer and precancer, especially in women with anovulatory cycles.
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4. Discuss the expected short term side effects following placement, including
unscheduled bleeding and cramping. Advise that many of these symptoms may
subside over time.
5. Discuss the intermediate and longer term effects of each IUD.
a. ParaGard: Monthly bleeding will increase by an average of 30-50%, but
that increase can usually be reversed by the use of NSAIDs during menses.
b. Mirena:
1) Unscheduled bleeding and spotting may be frequent in the first 4
months of use, but will diminish over time.
2) Total blood loss will be significantly reduced with longer use of Mirena.
3) 20% of women will have no spotting or bleeding at all by 12 months of
use. By that time, most other women will have only 1-3 days of spotting
a month.
4) Some women experience headaches or breast tenderness, especially
with early use, but usually the symptoms are only temporary or are due
to other causes.
5) Mirena is the most effective medical therapy for heavy or prolonged
menstrual bleeding. It may also help reduce dysmenorrhea.
c. Skyla:
1) Unscheduled bleeding and spotting may be frequent in the first 4
months of use, but will diminish over time.
2) Total blood loss will be significantly reduced with longer use.
3) 12% of women will have no spotting or bleeding at all by 3 years of
use.
4) Some women experience headaches or breast tenderness, especially
with early use, but usually the symptoms are only temporary or are due
to other causes.
6. Remind women that the pregnancy protection, non-contraceptive benefits and the
side effects disappear almost immediately following IUD removal.
Referral:
1. Any patient with US MEC category 3 and 4 conditions to IUD she desires to use.
2. Any patient who will need antibiotic prophylaxis for IUD placement.
3. Refer women desiring IUD with labile or uncontrolled hypertension.
Reference:
1. ACOG Practice Bulletin No. 114: Management of endometriosis. Obstet Gynecol.
2010;116(1):223-36.
2. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and
intrauterine devices. Obstet Gynecol. 2011;118(1):184-96.
3. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria
for Contraceptive Use 2012 Available at
http://www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm
4. Centers for Disease Control and Prevention. Sexually Transmitted Diseases
Treatment Guidelines. Available at http://www.cdc.gov/STD/treatment/
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5. Centers for Disease Control and Prevention. US Selected Practice Recommendations
for Contraceptive Use, 2013 MMWR Recomm Rep 1013; 62:1-60.
6. Flamant A, et al. Rates of continuation and satisfaction of immediate intrauterine
device insertion following first- or second- trimester surgical abortion: a French
prospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):268-74.
7. Grimes DA, et al. Cochrane systematic reviews of IUD trials: lessons learned.
Contraception. 2007;75(6 Suppl):S55-9.
8. Hatcher RA, et al (editors). Contraceptive Technology, 20th Ed. New York: Ardent
Media. 2011 147-192.
9. Hubacher C, et al. Side effects from the copper IUD: Do they decrease over time?
Contraception 2009;70:356-62.
10. Kaneshiro B, et al. Long term safety, efficacy and patient acceptability of the
intrauterine Copper-T-390A contraceptive device. Int J Women’s Health. 2010;2:21120.
11. Kaunitz AM, Bissonnette F, et al. Levonorgestrel-releasing intrauterine system or
medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial.
Obstet Gynecol. 2010;116(3):625-32.
12. Mirena website: http://www.mirena-us.com.
13. Nelson A. Intrauterine contraceptives. Glob Libr Women’s Med. (ISSN: 1756-2228)
2008 May. Available at:
http://www.glowm.com/?p=glowm.cml/section_view&articleid=393.
14. Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine
contraceptive systems: a randomized controlled trial. Obstet Gynecol.
2013;122(6):1205-13.
15. ParaGard website: http://www.paragard.com/hcp/resources-for-your-patients.
16. Sivin J. Utility and drawbacks of continuous use of a copper IUD for 20 years
Contraception 2007;75(6supp):S70-75.
17. Wiebe ER, et al. Motivation and experience of nulliparous women using intrauterine
contraceptive devices. J Obstet Gynaecol Can. 2010;32:335-8.
18. Whiteman MK, Tyler CP, Folger SG, et al. When can a woman have an intrauterine
device inserted? A systematic review. Contraception. 2013;87(5):666-73.
Intrauterine Device (IUD) Placement:
Definition:
This protocol outlines the steps needed to reconfirm that the patient is a candidate for the
intrauterine device (IUD) she desires and the steps to be followed in placing that IUD.
Whenever possible, IUD placement should be done at the initial visit to reduce barriers to access
and unintended pregnancy. Practice with plastic models helps reduce complications (especially
uterine perforation).
Subjective:
Must include:
1. LNMP and PMP.
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2. Patient previously assessed to be eligible for IUD use according to
Identification of Intrauterine Contraceptive Candidate protocol and
desires IUD placement after reading product consent form.
3. Medical and sexual history update with special attention to reconfirm IUD
candidacy.
4. No symptoms of pregnancy.
5. Reconfirm that this is an appropriate time for IUD placement.
Must exclude:
 Any US MEC Category 4 or 3 conditions for her desired IUD.
Objective:
Must include:
1. Blood pressure > 140/90, provide alternate method and refer to off campus
clinic for the IUD service.
2. If placing IUD in absence of recent pregnancy, must have normal pelvic
examination on day of placement demonstrating each of the following:
a. Complete uterine involution.
b. No sign of current vaginal or cervical infection.
c. No signs of pregnancy.
Must exclude:
 Any US MEC Category 4 condition or 3 conditions for her desired IUD.
Laboratory:


No Routine laboratory tests needed for IUD placement, except pregnancy
test if patient at risk.

Must exclude:
 Any laboratory results indicating a US MEC Category 4 or 3 conditions for
her desired IUD, such as current cervicitis, etc.
Assessment:
Candidate for placement of intrauterine contraceptive.
Plan:
1. Review patient product information brochure with patient, answer all her
questions, obtain her informed consent and have her sign all appropriate forms.
Place forms into patient’s record.
2. Premedication has not been found to decrease discomfort of IUD placement, but
may be indicated in the following situations:
 NSAIDs (Ibuprofen 400-600mg orally every 6 hours) to reduce cramping
after placement.
3. If patient found to have BV, treat with systemic not topical antibiotics. No need
to delay IUD placement, but reinforce the importance of taking her antibiotics.
4. If no recent pregnancy, place IUD according to manufacturer’s instructions with
close attention to aseptic technique. Important elements include:
a. Gently place tenaculum on the portion of the cervical lip that is
further away from introitus (e.g. posterior lip with anteverted
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5.

6.
7.

8.

9.

uterus) to straighten axis of uterus and to stabilize uterus. Apply
traction on tenaculum to reduce risk of perforation.
b. Careful uterine sounding to confirm that patient is candidate for
her desired IUD.
1) ParaGard 6.0-9.0 cm.
2) Mirena 6.0-10.0 cm.
3) Skyla – no dimensions set, but generally 6-10cm best.
c. Open IUD package, load IUD and place IUD following
manufacturer’s instructions.
d. Trim tailstrings to fit around cervix.
Write procedure note which records uterine position and size, depth of uterine
sounding, depth to which IUD placed, and length to which the tailstrings
trimmed, how well the patient tolerated the procedure, as well as any
complications that may have been encountered during the procedure. Document
IUD type, lot number and expiration date.
Instruct patient to return to clinic for routine well woman care and earlier PRN
problems with her IUD. No routine post-placement visit needed.
Provide backup method for 7 days is LNG IUS placed at any time other than
specified (e.g., within 7 days of LMP, delivery or at time of hormonal method
change).
Unless patient has contraindications to use of NSAIDs, advise use PRN problem
with cramping or bleeding. Typical recommendation: Ibuprofen 400-600 mg
orally every 6 hours when needed for cramping or heavy bleeding. Other
NSAIDs at equivalent doses may be used.
If patient has BP ≥140/90 verified at least one additional time in clinic with no
smoking or caffeine for 30 minutes, refer for evaluation of possible
hypertension.

Patient Education:
1. Reinforce IUD education, including checking strings monthly, signs and
symptoms of possible IUD complications (e.g. infection, expulsion,
perforation, pregnancy).
2. Instruct patient to seek care urgently if any symptoms of PID, pregnancy or
expulsion or if she experiences heavy vaginal bleeding or severe cramping.
3. Instruct patient to return for re-evaluation of appropriateness of method if she
becomes at risk for PID.
4. Instruct patient with ParaGard that IUD removal is recommended on label by
10 years, but that the actual length of use may be longer. On label the Mirena
should be changed every 5 years, but new information may change that
recommendation in the future. Skyla is approved for up to 3 years of use.
5. Encourage routine health care.
Referral:
1. Any patient who has difficult placement.
2. Any patient with elevated blood pressure or US MEC category 3 or 4 conditions
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3. Patient who presents for LNG IUS insertion at times in her cycle not specified
on product labeling.
4. Any patient who has history of any complication of IUD placement.
Reference:
1. ACOG Practice Bulletin No. 121: Long-acting reversible contraception:
Implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184-96.
2. Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine
device insertion. Cochrane Database of Systematic Reviews
2009;(3):CD007373.
3. Bergin A, Tristan S, Terplan M, et al. A missed opportunity for care: two-visit
IUD insertion protocols inhibit placement. Contraception. 2012;86(6):694-7.
4. Çelen Ş, Sucak A, Yıldız Y, et al. Immediate postplacental insertion of an
intrauterine contraceptive device during cesarean section. Contraception.
2011;84(3):240-3.
5. Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility
Criteria for Contraceptive Use, 2012. MMWR Recomm Rep. 2012;59(RR-4):186. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases
Treatment Guidelines. Available at http://www.cdc.gov/STD/treatment/ .
7. Centers for Disease Control and Prevention (CDC). US Selected Practice
Recommendations for Contraceptive Use, 2013 MMWR Recomm Rep
1013;62:1-60.
8. Chen BA, Reeves MF, Hayes JL, et al. Postplacental or delayed insertion of the
levonorgestrel intrauterine device after vaginal delivery: a randomized controlled
trial. Obstet Gynecol. 2010;116(5):1079-87.
9. Flamant A, Ouldamer L, Body G, et al. Rates of continuation and satisfaction of
immediate intrauterine device insertion following first- or second-trimester
surgical abortion: a French prospective cohort study. Eur J Obstet Gynecol
Reprod Biol. 2013;169(2):268-74.
10. Grimes DA, et al. Immediate post-partum insertion of intrauterine devices.
Cochrane Database Sys Rev. 2010;(5):CD003036.
11. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of
IUD trials: lessons learned. Contraception. 2007;75(6 Suppl):S55-9.
12. Grimes DA, et al. Antibiotic prophylaxis for intrauterine contraceptive device
insertion. Cochrane Database Sys Rev. 2001;(2):CD001327.
13. Hatcher RA, et al (editors). Contraceptive Technology, 20th Ed. New York:
Ardent Media. 2011 147-192.
14. Khadivzadeh T, Erfanian F. The effects of simulated patients and simulated
gynecologic models on student anxiety in providing IUD services. Simul
Healthc. 2012;7(5):282-7.
15. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period:
a systematic review. Contraception. 2009;80(4):327-36.
16. Nelson A. Intrauterine contraceptives. Glob Libr Women’s Med. (ISSN: 17562228) 2008 May. Available at:
http://www.glowm.com/?p=glowm.cml/section_view&articleid=393.
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17. Nelson AL, Chen S, Eden R. Intraoperative placement of the Copper T-380
intrauterine devices in women undergoing elective cesarean delivery: a pilot
study. Contraception. 2009;80(1):81-3.
18. ParaGard website: http://www.paragard.com/hcp/resources-for-your-patient.
19. Scavuzzi A, Souza AS, Costa AA, et al. Misoprostol prior to inserting an
intrauterine device in nulligravidas: a randomized clinical trial. Hum Reprod.
2013;28(8):2118-25.
20. Shimoni N, Davis A, Ramos ME, et al. Timing of copper intrauterine device
insertion after medical abortion: a randomized controlled trial. Obstet Gynecol.
2011;118(3):623-8.
21. Steenland MW, Tepper NK, Curtis KM, et al. Intrauterine contraceptive
insertion postabortion: a systematic review. Contraception. 2011;84(5):447-64.
22. Sufrin CB, Postlethwaite D, Armstrong MA, et al. Neisseria gonorrhea and
Chlamydia trachomatis screening at intrauterine device insertion and pelvic
inflammatory disease. Obstet Gynecol. 2012;120(6):1314-21.
23. Whiteman MK, Tyler CP, Folger SG, et al. When can a woman have an
intrauterine device inserted? A systematic review. Contraception.
2013;87(5):666-73.
24. Wilson W, Taubert KA, Gewitz M, et al. American Heart Association
Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; et al.
Prevention of infective endocarditis: guidelines from the American Heart
Association: a guideline from the American Heart Association Rheumatic Fever,
Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular
Disease in the Young, and the Council on Clinical Cardiology, Council on
Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes
Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736-54. .
Erratum in: Circulation. 2007;116(15):e376-7. Available at:
http://circ.ahajournals.org/content/116/15/1736.full.pdf+html.
IUD Removal:
Definition: Steps to follow in removing a patient’s Intrauterine Device (IUD).
Subjective:
Must include:
1. NMP and PMP.
2. Medical and sexual history update.
3. History of any recent intercourse, if patient not currently menstruating (may
want to delay removal if recent exposure).
4. Documentation of reason for IUD removal request.
5. If patient wants to continue IUD use, but is requesting removal because her
IUD has been in place for the number of years for which it is recommended,
refer patient to off campus clinics such as Planned Parenthood Clinic or
Community Health Center for the service.
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Objective:
Must exclude: BP > 140/90
Must include:
1. BP<140/90
2. Pelvic examination—Check for any signs of infection or incorrect IUD
placement.
Laboratory:
Must include:
1. Hgb/Hct (if history of excessive bleeding).
2. Negative sensitive pregnancy test.
Assessment:
Candidate for IUD removal.
Plan:
1. If IUD strings visible:
a. Obtain patient’s informed consent for IUD removal acknowledging the
risks of bleeding, pain, infection and failure to remove.
b. If there are any signs or symptoms of cervical infection or PID, provide
appropriate systemic antibiotics and administer first dose prior to removal.
c. If the patient required antibiotic prophylaxis against endocarditis by AHA
guidelines when she had her IUD placed, refer this patient to off campus
clinic for IUD service.
d. Remove IUD following manufacturer’s instructions.
e. For postmenopausal women with stenotic os, refer this patient to off
campus clinic for IUD service.
2. If IUD string(s) are missing or break during removal attempt, refer patient to
off campus clinic for IUD service.
3. If IUD has been in place for more than 5 years or if patient has been
experiencing any signs or symptoms of upper tract infection (e.g., vaginal
discharge or lower abdominal pain), refer patient to off campus clinic for care
& IUD service.
4. If patient seeking pregnancy, provide preconceptional counseling.
5. If patient desires contraception:
a. If patient has re-qualified for an IUD, do not remove IUD and refer patient
to an off campus clinic for IUD service.
b. If patient desires another method, provide it.
6. If patient has had intercourse in the last five days and is at risk for pregnancy
if IUD removed, offer emergency contraception or delay removal of IUD.
7. If patient with no prior history of hypertension has BP ≥ 140/90 verified at
least one additional time this visit with no smoking or caffeine for 30 minutes,
refer for evaluation of possible hypertension.
Patient Education:
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1. Counsel regarding risk of pregnancy or ectopic pregnancy if IUD removed in
absence of menses with recent intercourse; tell patient IUD no longer protects
her from pregnancy. Encourage EC use.
2. Encourage women desire IUD removal in order to become pregnant to take
folic acid supplement for at least 1 – 3 months prior to removal or at least to
conception.
3. Advise women who have IUD removed but are not seeking pregnancy to
immediately initiate another effective method. Remind them that the IUD
provides no residual contraceptive protection once it is removed.
Referral:
1. Patient who requires antibiotic prophylaxis for prevention of endocarditis.
2. A patient with elevated BP or difficult IUD removal.
Reference:
1. ACOG Practice Bulletin No. 121: Long-acting reversible contraception:
Implants and intrauterine devices. Obstet Gynecol. 2011 Jul;118(1):184-96.
2. Centers for Disease Control and Prevention. U.S. medical eligibility criteria
for contraceptive use, 2010. MMWR. Morb Mortal Wkly Rep. 2010;59:1-6.
Available at http//www.cdc.gov/mmwr/preview/mmwrhtm/rr59e0528al/htm.
3. Centers for Disease Control and Prevention (CDC). US Selected Practice
Recommendations for Contraceptive Use, 2013 MMWR Recomm Rep
1013;62:1-60.
4. Hatcher RA, et al (editors).Contraceptive Technology 20th edition Ardent
Media. New York, NY 2011:147-92.
5. Hou SP, Chen OJ, Huang LH, et al. Medical methods for cervical ripening
before the removal of intrauterine devices in postmenopausal women: a
systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):130-42.
6. Nelson AL. Intrauterine contraceptives. Glob.libr.women’s med., Available at:
http://www.glowm.com/
7. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20
years. Contraception. 2007;75(6 Suppl):S70-5.
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List of supplies for IUC procedure:
All lab results – Pap/GC/ CT
Consent form for Paraguard or Mirena
Ibuprofen (600 – 800 mg)
Speculum
Cotton swab (a bunch in a basin or a small basket)
Betadine swabs (3)
Tenaculum
Sound (plastic or metal)
IUC – Paraguard or Mirena
Sterile gloves
Scissors
Silver Nitrate or Monsel solution
Maxi Pads
IUC information card
Slip for f/u appt (after first menstrual period)
Smelling salt
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Appedix B-4: NEXPLANON –SOAP template
S:

LNMP:_______________ PMP:________________ Current Contraceptive:__________________

Last Pap:________________ Last CT/GC test:___________________ G___ P___ Tab___ Sab___
I.

II.

III.

O:

Absolute Contraindications: None /Other:
1. Known or suspect pregnancy
2. Current or past history of DVT/PE
3. Liver tumors/active liver disease
4. Hypersensitivity to any component of NEXPLANON
5. Undiagnosed vaginal bleeding
6. Current or past history of breast cancer
7. Lupus
8. < 4 weeks postpartum
Relative Contraindications: None /Other:
1. HIV+ / immunosuppressed
2. Ischemic heart disease or stroke history
3. Desired pregnancy before 1 year
4. WT > 30% BMI
Risk Factors for STD’s’: None /Other:
1. Multiple partners
2. High risk partner (multiple partners, injection drugs, HIV risk)
3. Increased risk HIV
No Exam

1.
2.
3.

See previous pap / other lab results
Pregnancy test result: Negative / Positive (Date:
Pelvic Exam:

)

A: V25.43 Implanon Surveillance; NEXPALNON information & consent visit
P:

Reviewed the following with patient:
1.
2.
3.
4.
5.
6.
7.
8.

Other available contraceptives
NEXPLANON benefits
NEXPLANON insertion procedure / NEXPLANON removal procedure
NEXPLANON ROD check procedure
NEXPLANON problems, risks, side-effects
NEXPLANON cost
NEXPLANON Consent Form Reviewed and signed
Patient to make insertion visit / follow up visit as desired
Adopted the form (last revised 03/14) from University Health Services, Tang Center, University of
California, Berkeley.
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Appendix C

71

Adding LARC Services into Student Health

Appendix D Project Gantt Chart

Table 1. Project Gantt Chart
Task1
Task2
Task3
Task4
Task4
Task5
Task6
Task7
Task6

Task
Chart review
Data analysis
Staff training
Online Ad
Final prep
Service launch
f/u chart review
Data analysis
final report for audit

start date
1/25/2014
3/16/2014
3/20/2014
10/1/2014
7/1/2014
10/1/2014
1/5/2015
2/6/2015
3/1/2015

duration
49
35
163
80
91
84
31
22
29

complete date
3/15/2014
4/20/2014
8/30/2014
12/20/2014
9/30/2014
12/24/2014
2/5/2015
2/28/2015
3/30/2015

Chart 1. Project Gantt Chart
1/1/2014

4/11/2014

7/20/2014 10/28/2014

2/5/2015

5/16/2015

Chart review
Data analysis
Staff training
Online Ad

Final prep

start date
duration

Service launch
f/u chart review
Data analysis
final report for audit
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Appendix E Failure Mode, Effect, and Criticality Analysis for LARC service
Process

Copper T IUD
procedure as
emergency
contraception

Care provided by
Administration
new/inexperienced of Copper T
provider
IUD

Potential/Failure
Mode

No emergency
response team;
no back up
experienced
gynecologist

Inexperienced
provider

Adverse events
such uterine
perforation

Potential/Effect
on Patient

5

5

10

Frequency of
Failure Mode

2

5

2

Likelihood of
Reaching Patient

2

5

2

Criticality of
Failure Mode

20

125

40

Root Causes

No standard
No supervision for
clinical
inexperienced
guidelines to
providers
require a back-up
gynecologist

Not familiar with
possible adverse
effects of the
procedure

Strategies for
Improvement

Develop a
system guideline
for emergency
response; policy
for patient
referral process;
training and
checking
competency by a
contract
gynecologist

Risk prevention
& elimination
plan prior to
project; patient
care by
emergency
response team;
guidelines for
patient care and
care transfer;

Observing 3-5
procedures before
hand-on;
periodical
competency
review; continue
education to
update skills;

Patient
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Appendix F Contraceptive Method Data Collection Form (2013 & 2014)
Date

Appendix E-1. Contraceptive Method Data Collection Form (06/24-12/20/2013)
Age group
continue use of a method
< 20
> 30
<6m
21 - 24
25-29
>6m
> 12m

total

ancy

Bir

th

Co
n tr
ol

Me
th o
ds

Never
n
Preg
History of
Unknown
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Yes
tn er
Par
No
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Pills
Patch
Ring
Injection
*Condom
Implant
Mirena
Paragard
Skyla
**Other
**other includes not use any method, coitus interuptus, film, etc.
* "Condom" may include other types of barrier methods.

Appendix E-2. Contraceptive Method Data Collection Form (06/24-12/20/2014)
new form up to age 20 age 21 - 24 age 25 - 29 age 30 & > use < 6m use > 6 m use > 12m C/Initiate
G0
…………..
> G1
………….
G???
…………
…………………………………………………………………………………………….
……….
partner-y
………..
partner-N
XXXXXXXXXXXXXXXXXXXXXXXX ………….
partner???
XXXXXXXXXXXXXXXXXXXXXXXX …………..
………………………………………………………………………………………………………………………………………………….………….
OCP
…………
patch
………..
ring
……………
Depo-inj.
…………
condom
………….
implant
mirena
paragard
skyla
other
…………

Total

…………
……………
……………
……………
…………….

*other includes no BCM, coitus interuptus, film, etc.
* "Condom" may include other types of barrier methods.
* C/I: Counseling, to initiate, or to refer/Initiating
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Appendix G-1 Initial WBS
Promoting &
Launching
LARCs

Final Prep

Provider
Training/Skill
Refresh

Staff Training

Online Ad

Provider
meeting

QI meeting

Data Analysis

Data
Collection

Chart Review

G-2 WBS for Follow-up QI study

Quality LARC
service

QI meeting

Data Analysis
& QI Report

Chart Review
& Data
Collection

Skill Update

Refresher
training

Service Survey

Staff Survey

Patient Survey
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Appendix I Ishikawa Diagram

Equipment

Brainstorm
LARCs

Training

QI & Staff
meeting

Instrument

Mentoring

Policy &
Procedures

Admin
Support
Super bill
Supplies for
procedure

Charting
Template

Material

Personnel

Process

Exam Room

Environment

Skill update
LARC
Service
F/U QI
Study

Satisfaction
Survey
Baseline QI
Study

Measurement
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Appendix J
Table 1. Observation of Contraceptive Use from Women’s Health Visits in June-December 2013

visits 2013 q4w Total
6/24/2013
85
7/22/2013
62
8/19/2013
67
9/16/2013
223
10/14/2013
300
11/11/2013
294
Total visits
1031

< 24 yo OC/Patch/Ring Injection Implant
IUC
Other
66(78%)
31/1/1
6
0
M4/P0
38
48(77%)
33/2/1
1
0
M1/P2
23
48(72%)
30/3/1
1
0
M4/P1
29
116(52%)
109/6/10
20
2
M2/P2
75
240(80%)
135/4/8
27
4
M6/P1
97
222(76%)
126/11/11
21
4
M4/P5
112
733(71%) 464/28/32(50%) 76% (75) 10(1%) M21/P11(3%) 347(37%)

IUC-Intrauterine Contarceptives; M-Mirena; P-Paragard

Chart 1 Current Contraceptive Used (June-December 2013)

Other
37%

OC/Patch/Ring
52%

IUC
3% Implant
1%

DMPA
7%
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Appendix K-1
Budget Projection for LARCs Purchase and Reimburse

LARC service
Month1 Month2 Month3
Month4 Month5
Month6
total
LARC/units
need per
month
3
6
3
8
8
4
32
Reimbursed
for
procedures
provided
each month
$2,571
$4,285
$2,571
$6,856
$6,856
$3,428
$27,424
pre-paid
(total of 15
units)
($2,130) ($4,260)
($2,130) ($2,130)
($10,650)

A smaller number of LARC services will be expected for the first 6 months and during the quarter breaks.
Appendix K-2
Budget Projection for Implant Contraceptive (approved in late October, 2014)

Month1 Month2 Month3
Month4 Month5
Month6
total
LARC/units
need per
month
3
6
3
8
8
4
32
Reimbursed
for
procedures
provided
each month
$2,690
$5,380
$2,690 $7,170
$7,170
$3,580 $28,690
pre-paid
(total of 5
units)
($1,980) ($1,320)
($3,300)
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Appendix L
Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use (Updated in June 2012)

Medical Eligibility Criteria Categories
1 = A condition for which there is no restriction for the use of the contraceptive method.
2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
4 = A condition that represents an unacceptable health risk if the contraceptive method is used.
http://www.arhp.org/uploadDocs/choosingqrg.pdf
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Age

Anatomic
abnormalities
Anemias

Benign ovarian
tumors
Breast disease

a) Distorted uterine cavity
b) Other abnormalities
a) Thalassemia
b) Sickle cell disease‡
c) Iron-deficiency anemia
(including cysts)
a) Undiagnosed mass
b) Benign breast disease
c) Family history of cancer
d) Breast cancer‡
i) current
ii) past and no evidence of
current disease for 5 years
a) < 1 month postpartum
b) 1 month or more postpartum

Breastfeeding
(see also
Postpartum)
Cervical cancer
Awaiting treatment
Cervical ectropion
Cervical
intraepithelial
neoplasia
Cirrhosis
a) Mild (compensated)
b) Severe‡ (decompensated)
Deep venous
a) History of DVT/PE, not on
thrombosis
anticoagulant therapy
(DVT)
i) higher risk for recurrent
/Pulmonary
DVT/PE
embolism (PE)
ii) lower risk for recurrent
DVT/PE
b) Acute DVT/PE
c) DVT/PE and established on
anticoagulant therapy for at least 3
months
i) higher risk for recurrent
DVT/PE
ii) lower risk for recurrent
DVT/PE
d) Family history (first-degree
relatives)
e) Major surgery
(i) with prolonged
immobilization
(ii) without prolonged
immobilization
f) Minor surgery without
immobilization
Depressive
disorders
Diabetes mellitus a) History of gestational DM only
(DM)
b) Non-vascular disease
Diabetes mellitus
(i) non-insulin dependent
(cont.)
(ii) insulin dependent‡
c) Nephropathy/ retinopathy/
neuropathy‡
d) Other vascular disease or
diabetes of >20 years' duration‡
Endometrial
cancer‡
Endometrial
hyperplasia
Endometriosis
Epilepsy‡
(see also Drug Interactions)
Gallbladder
a) Symptomatic
disease
(i) treated by
cholecystectomy
(ii) medically treated
(iii) current
b) Asymptomatic
Gestational
a) Decreasing or
trophoblastic
undetectable ß-hCG levels

Copper-IUD

LNG--IUD

Implant

Injection

Progestin-only pill

Combined pill,
patch, ring

Sub-condition

Condition
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I
C
I
C
I
C
I
C
I
C
I
C
Menarche Menarche to <18=1 Menarche to <18=2 Menarche to <18=1 Menarche to <20=2 Menarche to <20=2
to <40=1
>40=2
18-45=1
18-45=1
18-45=1
>20=1
>20=1
>45=1
>45=2
>45=1
4
4
2
2
1
1
1
1
1
2
2
1
1
1
1
2
1
1
1
1
1
2
1
1
1
1
1
1
2*
1
1

2*
1
1

2*
1
1

2*
1
1

2
1
1

1
1
1

4
3

4
3

4
3

4
3

4
3

1
1

3*
2*

2*
1*

2*
1*

2*
1*

2
1
2

1
1
1

2
1
2

2
1
2

1
4

1
3

1
3

4

2

3

4

2

4

2

1
2

1
1

1
3

1
3

1
1

2

2

2

1

2

2

2

2

1

4

2

2

2

2

2

4*

2

2

2

2

2

3*

2

2

2

2

2

2

1

1

1

1

1

4

2

2

2

2

1

2

1

1

1

1

1

1

1

1

1

1

1

1*

1*

1*

1*

1*

1*

1

1

1

1

1

1

2
2
3/4*

2
2
2

2
2
3

2
2
2

2
2
2

1
1
1

3/4*

2

3

2

2

1

1

1

1

1

1

1

1

1

1

1

1
1*

1
1*

1
1*

1
1*

1
1

2
1

2

2

2

2

2

1

3
3
2
1

2
2
2
1

2
2
2
1

2
2
2
1

2
2
2
3

1
1
1
3

4

2

4

2
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I
disease

Headaches

History of
bariatric
surgery‡
History of
cholestasis
History of high
blood pressure
during pregnancy
History of pelvic
surgery
HIV

Hyperlipidemias
Hypertension

Inflammatory
bowel disease
Ischemic heart
disease‡
Liver tumors

b) Persistently elevated
ß-hCG levels or
malignant disease‡
a) Non-migrainous
b) Migraine
i) without aura, age <35
ii) without aura, age >35
iii) with aura, any age
a) Restrictive procedures
b) Malabsorptive procedures
a) Pregnancy-related
b) Past COC-related

High risk
HIV infected
(see also Drug Interactions)‡
AIDS
(see also Drug Interactions) ‡
Clinically well on therapy
a) Adequately controlled
hypertension
b) Elevated blood pressure levels
(properly taken measurements)
(i) systolic 140-159 or diastolic
90-99
(ii) systolic ≥160 or diastolic
≥100‡
c) Vascular disease
(Ulcerative colitis, Crohn’s
disease)
Current and history of
a) Benign
i) Focal nodular hyperplasia
ii) Hepatocellular adenoma‡
b) Malignant‡

Malaria
Multiple risk
(such as older age, smoking,
factors for arterial diabetes and hypertension)
cardiovascular
disease
Obesity
a) >30 kg/m2 body mass index
(BMI)
b) Menarche to < 18 years and >
30 kg/m2 BMI
Ovarian cancer‡
Parity
Past ectopic
pregnancy
Pelvic
inflammatory
disease

Peripartum
cardiomyopathy‡

Postabortion

Postpartum
(see also
Breastfeeding)

a) Nulliparous
b) Parous

a) Past, (assuming no current risk
factors of STIs)
(i) with subsequent pregnancy
(ii) without subsequent
pregnancy
b) Current
a) Normal or mildly impaired
cardiac function
(i) < 6 months
(ii) > 6 months
b) Moderately or severely
impaired cardiac function
a) First trimester
b) Second trimester
c) Immediately post-septic
abortion
a) < 21 days
b) 21 days to 42 days
(i) with other risk factors for
VTE

C

I

1

C

I

1

C

I

1

Copper-IUD

LNG--IUD

Implant

Injection

Progestin-only pill

Combined pill,
patch, ring

Sub-condition

Condition
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C

I

1

C

I

4

C
4

1*

2*

1*

1*

1*

1*

1*

1*

1*

1*

1*

2*
3*
4*

3*
4*
4*

1*
1*
2*

2*
2*
3*

2*
2*
2*

2*
2*
3*

2*
2*
2*

2*
2*
3*

2*
2*
2*

2*
2*
3*

1
COCs: 3
P/R: 1
2
3
2

1
3

1
1

1
1

1
1

1*
1*
1*
1
1

1
2
1

1
2
1

1
2
1

1
2
1

1
1
1

1

1

1

1

1

1

1
1*

1
1*

1*
1*

1
1*

2
2

2
2

2
2

2
2

1*

1*

1*

3

2*

3

2*

2

2

2

1*

2/3*
3*

If on treatment, see Drug Interactions
2*
2*
1*
2*

2

2*
1*

2*
1

1*
1

3

1

2

1

1

1

4

2

3

2

2

1

4
2/3*

2
2

3
2

2
1

2
1

1
1

4

2

3

3

2

3

2

3

1

2
4
4
1
3/4*

2
3
3
1
2*

2
3
3
1
3*

2
3
3
1
2*

2
3
3
1
2

1
1
1
1
1

2

1

1

1

1

1

2

1

2

1

1

1

1
1
1
1

1
1
1
2

1
1
1
1

1
1
1
1

1
2
1
1

1
2
1
1

1
1

1
1

1
1

1
1

1
2

1
2

1
2

1
2

1

1

1

1

4

2*

4

2*

4
3
4

1
1
2

1
1
2

1
1
2

2
2
2

2
2
2

1*
1*
1*

1*
1*
1*

1*
1*
1*

1*
1*
1*

1*
2
4

1*
2
4

4

1

1

1

3*

1

1

1
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I
(ii) without other risk factors
for VTE
c) > 42 days
Postpartum (in
a) < 10 minutes after delivery of
breastfeeding or
the placenta
non-breastfeeding b) 10 minutes after delivery of the
women, including
placenta to < 4 weeks
post-cesarean
c) > 4 weeks
section)
d) Puerperal sepsis
Pregnancy
Rheumatoid
a) On immunosuppressive therapy
arthritis
b) Not on immunosuppressive
therapy
Schistosomiasis
a) Uncomplicated
b) Fibrosis of the liver‡
Severe
dysmenorrhea
Sexually
a) Current purulent cervicitis or
transmitted
chlamydial infection or gonorrhea
infections (STIs) b) Other STIs (excluding HIV and
hepatitis)
Sexually
c) Vaginitis (including
transmitted
trichomonas vaginalis and
infections
bacterial vaginosis)
(cont.)
d) Increased risk of STIs
Smoking
a) Age < 35
b) Age > 35, < 15 cigarettes/day
c) Age > 35, >15 cigarettes/day
Solid organ
a) Complicated
transplantation‡
b) Uncomplicated
Stroke‡
Superficial
venous
thrombosis
Systemic lupus
erythematosus‡

History of cerebrovascular
accident
a) Varicose veins
b) Superficial thrombophlebitis
a) Positive (or unknown)
antiphospholipid antibodies
b) Severe thrombocytopenia
c) Immunosuppressive treatment
d) None of the above

Thrombogenic
mutations‡
Thyroid disorders Simple goiter/
hyperthyroid/hypothyroid
Tuberculosis‡
a) Non-pelvic
(see also Drug
b) Pelvic
Interactions)
Unexplained
(suspicious for serious condition)
vaginal bleeding before evaluation
Uterine fibroids
Valvular heart
a) Uncomplicated
disease
b) Complicated‡
Vaginal
a) Irregular pattern without heavy
bleeding
bleeding
patterns
b) Heavy or prolonged bleeding
Viral hepatitis
a) Acute or flare
b) Carrier/Chronic
Drug Interactions
Antiretroviral
a) Nucleoside reverse
therapy
transcriptase inhibitors
b) Non-nucleoside reverse
transcriptase inhibitors
c) Ritonavir-boosted protease
inhibitors
Anticonvulsant
a) Certain anticonvulsants
therapy
(phenytoin, carbamazepine,
barbiturates, primidone,
topiramate, oxcarbazepine)
b) Lamotrigine
Antimicrobial
a) Broad spectrum antibiotics
therapy
b) Antifungals
c) Antiparasitics
d) Rifampicin or rifabutin therapy

C

I

C

I

C

Copper-IUD

LNG--IUD

Implant

Injection

Progestin-only pill

Combined pill,
patch, ring

Sub-condition

Condition
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I

C

2

1

1

1

1

1

1

1

I

C

I

C

2

1

2

2

1
4
4*

1
4
4*

NA*
2

NA*
1

NA*
2/3*

NA*
1

2

1

2

1

1

1

1
1
1

1
1
1

1
1
1

1
1
1

1
1
1

1
1
2

1

1

1

1

4

2*

4

2*

1

1

1

1

2

2

2

2

1

1

1

1

2

2

2

2

1
2
3
4

1
1
1
1

1
1
1
1

1
1
1
1

2/3*

2

2/3*

4
2*
4

2
2

2
2
3

2
2

3

2

3

2

1
1

2

1

2

1
1
1

3

2
1
1
1

2

3

2

2
2

2
1

1
1

1
1

1
2

1
1

4

3

3

3

3

3

1

1

2
2
2
4*

2
2
2
2*

3
2
2

2
2
2

2
2
2
2*

2*
2
2
2*

3*
2
1

2*
1
1

2*

1
1

1

1*

1

1

1

1

1

1*
1*

1*
1*

1*
1*

1*
1*

1

1

4

2*

2*

3*

3*

4*

1
2
4
1

1
1
1
2

1
1
1
2

1
1
1
2

1*
3/4*
2
1
1

2*
1
1

2*
1
1

2*
1
1

1*

1*

1

1

1

2/3*

2*

2/3*

2*

2*

2*

1

2*

2/3*

2*

2/3*

2*

3*

3*

1

2*

2/3*

2*

2/3*

2*

3*

3*

1

2*

1

1

3*
1
1
1
3*

1
1
1
1
3*

1
1
1
1
1

1
1
1
1
2*

1
1
1
1
1

1
1
1
1
1

1
3

4

2*

4*

2
1
1
1

3
2*
2
1
1
1

1
2*

2*
1
1

1
1
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I = initiation of contraceptive method; C = continuation of contraceptive method; NA = Not applicable
* Please see the complete guidance for a clarification to this classification: www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm
‡ Condition that exposes a woman to increased risk as a result of unintended pregnancy.
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Table 1. Description of Studies Included
Study

Year
Study Design
Published

Goal(s) of Study

Study Outcomes

Mestad,
Secura,
Allsworth,
Madden,
Zhao, &
Peipert

2011

A longitudinal
observational
study

Contraceptive
method
preferences by age

LARCs were chose by 70% of
study participants.
Subcutaneous Implants were
preferred among age 14-17 and
IUDs were preferred among age
18-20.

Fanarjian,
Drostin,
Garret, &
Montalvo

2012

Retrospective
cohort study

The effectiveness
of free IUC in
reducing
pregnancy rates
among lowincome women.

No pregnancy per 100 women
years were found in the IUD
user group and 16.2 pregnancies
per 100 women years in the nonIUD user group

Godfrey &
colleagues

2010

A Multicenter The effectiveness
randomized
and continuation
controlled pilot rates of LARCs
study

At 6-month f/u, the continuation
rate was 75% in the LNG-IUS
group vs 45% in the Copper T
IUD group. 100% of LNG-IUS
group and 83% in Copper T
group planned to continue the
use of IUC after the study.

Short,
Dallay,
Omokanye,
Hanisch, &
Inki

2012

One-year
results of an
observational
study

The acceptability
of LNG-IUS and
ENG-implant use
among age 20-35
years European
women

The 12-month continuation rates
were 93% in LNG-IUS group
and 86% for the ENG-implant
group. About 62% of LNG-IUS
users were satisfied with their
method compared to 36% of the
ENG-implant user.

Deans &
Grimes

2009

A systematic
review of 6
cohort study
and 7 caseseries studies

IUD use among
adolescents for
continuation and
pregnancy rates

The IUD has similar or better
continuation rates compared to
combined oral contraceptives.
The cumulative pregnancy rate
among IUD users was 2 % at 6
months to 11% at 48 months.
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Table 2. Evaluation of Studies Using the STROBE Checklist
STROBE

Mestad

Fanarjian

Godfrey

Short

Deans*

1a

Y

Y

Y

Y

Y

1b

Y

Y

Y

Y

Y

2

Y

Y

Y

Y

Y

3

Y

Y

Y

Y

Y

4

Y

Y

Y

Y

Y

5

Y

Y

Y

Y

Y

6

Y

Y

Y

Y

Y

7

Y

Y

Y

Y

Y

8

Y

Y

Y

Y

N

9

Y

Y

Y

Y

Y

10

Y

Y

Y

Y

Y

11

Y

Y

Y

Y

N

12

Y

Y

Y

Y

N

13

Y

Y

Y

Y

Y

14

Y

Y

Y

Y

Y

15

Y

Y

Y

Y

N

16

Y

Y

Y

Y

N

17

Y

Y

Y

Y

Y

18

Y

Y

Y

Y

Y

19

Y

Y

Y

Y

Y

20

Y

Y

Y

Y

Y

21

Y

Y

Y

Y

Y

22

Y

Y

Y

Y

N

Continued on next page
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STROBE Statement—checklist of items that should be included in reports of observational
studies

Title and abstract

Item
No
1

Recommendation
(a) Indicate the study’s design with a commonly used term in the title or the
abstract
(b) Provide in the abstract an informative and balanced summary of what was
done and what was found

Introduction
Background/rationale

2

Explain the scientific background and rationale for the investigation being
reported

Objectives

3

State specific objectives, including any prespecified hypotheses

Methods
Study design

4

Present key elements of study design early in the paper

Setting

5

Describe the setting, locations, and relevant dates, including periods of

Participants

6

recruitment, exposure, follow-up, and data collection
(a) Cohort study—Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of
case ascertainment and control selection. Give the rationale for the choice of
cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods
of selection of participants
(b) Cohort study—For matched studies, give matching criteria and number of
exposed and unexposed
Case-control study—For matched studies, give matching criteria and the number
of controls per case
Variables

7

Clearly define all outcomes, exposures, predictors, potential confounders, and
effect modifiers. Give diagnostic criteria, if applicable

Data sources/

8*

measurement

For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if
there is more than one group

Bias

9

Describe any efforts to address potential sources of bias

Study size

10

Explain how the study size was arrived at

Quantitative variables

11

Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why

Statistical methods

12

(a) Describe all statistical methods, including those used to control for
confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
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Case-control study—If applicable, explain how matching of cases and controls
was addressed
Cross-sectional study—If applicable, describe analytical methods taking account
of sampling strategy
(e) Describe any sensitivity analyses
Continued on next page
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Results
Participants

13*

(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,
examined for eligibility, confirmed eligible, included in the study, completing follow-up,
and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram

Descriptive

14*

data

(a) Give characteristics of study participants (eg demographic, clinical, social) and
information on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarise follow-up time (eg, average and total amount)

Outcome data

15*

Cohort study—Report numbers of outcome events or summary measures over time
Case-control study—Report numbers in each exposure category, or summary measures of
exposure
Cross-sectional study—Report numbers of outcome events or summary measures

Main results

16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for
and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period

Other analyses

17

Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
analyses

Discussion
Key results

18

Summarise key results with reference to study objectives

Limitations

19

Discuss limitations of the study, taking into account sources of potential bias or

Interpretation

20

imprecision. Discuss both direction and magnitude of any potential bias
Give a cautious overall interpretation of results considering objectives, limitations,
multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability

21

Other information
Funding
22

Discuss the generalisability (external validity) of the study results
Give the source of funding and the role of the funders for the present study and, if
applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and
unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background
and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article
(freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine
at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is
available at www.strobe-statement.org.
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Table 4. Provider LARC Training Plan
Implant Contraceptive

IUD

Lecture

All completed & certified

3 providers completed

Simulation Lab/practice
model

All completed/own
individual practice model

3 providers completed/a
refresher lab needed

Observation (optional)

In progress

Not approved/ prn

Supervised insertion

3 cases

5 cases

Supervised removal

3 cases

0
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